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A B S T R A C T
Background
Cardiac and thoracic surgery are associated with an increased risk of venous thromboembolism (VTE). The safety and efficacy of
primary thromboprophylaxis in patients undergoing these types of surgery is uncertain.
Objectives
To assess the effects of primary thromboprophylaxis on the incidence of symptomatic VTE and major bleeding in patients undergoing
cardiac or thoracic surgery.
Search methods
The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May
2014) and CENTRAL (2014, Issue 4). The authors searched the reference lists of relevant studies, conference proceedings, and clinical
trial registries.
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs comparing any oral or parenteral anticoagulant or mechanical intervention to
no intervention or placebo, or comparing two different anticoagulants.
Data collection and analysis
We extracted data on methodological quality, participant characteristics, interventions, and outcomes including symptomatic VTE and
major bleeding as the primary effectiveness and safety outcomes, respectively.
1Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We identified 12 RCTs and one quasi-RCT (6923 participants), six for cardiac surgery (3359 participants) and seven for thoracic
surgery (3564 participants). No study evaluated fondaparinux, the new oral direct thrombin, direct factor Xa inhibitors, or caval filters.
All studies had major study design flaws and most lacked a placebo or no treatment control group. We typically graded the quality
of the overall body of evidence for the various outcomes and comparisons as low, due to imprecise estimates of effect and risk of
bias. We could not pool data because of the different comparisons and the lack of data. In cardiac surgery, 71 symptomatic VTEs
occurred in 3040 participants from four studies. In a study of 2551 participants, representing 85% of the review population in cardiac
surgery, the combination of unfractionated heparin with pneumatic compression stockings was associated with a 61% reduction of
symptomatic VTE compared to unfractionated heparin alone (1.5% versus 4.0%; risk ratio (RR) 0.39; 95% confidence interval (CI)
0.23 to 0.64). Major bleeding was only reported in one study, which found a higher incidence with vitamin K antagonists compared to
platelet inhibitors (11.3% versus 1.6%, RR 7.06; 95% CI 1.64 to 30.40). In thoracic surgery, 15 symptomatic VTEs occurred in 2890
participants from six studies. In the largest study evaluating unfractionated heparin versus an inactive control the rates of symptomatic
VTE were 0.7% versus 0%, respectively, giving a RR of 6.71 (95% CI 0.40 to 112.65). There was insufficient evidence to determine if
there was a difference in the risk of major bleeding from two studies evaluating fixed-dose versus weight-adjusted low molecular weight
heparin (2.7% versus 8.1%, RR 0.33; 95% CI 0.07 to 1.60) and unfractionated heparin versus low molecular weight heparin (6% and
4%, RR 1.50; 95% CI 0.26 to 8.60).
Authors’ conclusions
The evidence regarding the efficacy and safety of thromboprophylaxis in cardiac and thoracic surgery is limited. Data for important
outcomes such as pulmonary embolism ormajor bleeding were often lacking. Given the uncertainties around the benefit-to-risk balance,
no conclusions can be drawn and a case-by-case risk evaluation of VTE and bleeding remains preferable.
P L A I N L A N G U A G E S U M M A R Y
Prevention of blood clots in patients undergoing cardiac or thoracic surgery
Background
Patients undergoing surgery have an increased probability of developing blood clots in their veins (venous thromboembolism). These
clots may be in the deep veins (deep vein thrombosis) or travel to the lungs (pulmonary embolism). As in other types of surgery,
effective prevention of blood clots (thromboprophylaxis) after cardiac or thoracic surgery may reduce the risk of postoperative vein
clots. These potential benefits, however, have to be balanced against the associated risks of bleeding. This systematic review looked at
the effectiveness and safety of anticoagulants (medicines that reduce the ability of the blood to clot), mechanical interventions (such
as pneumatic pumps on the legs to promote blood flow), and caval filters (a type of vascular filter, implanted into the main abdominal
vein to prevent movement of clots from the legs to the lungs) in patients undergoing cardiac or thoracic surgery.
Study characteristics and key results
We identified 13 randomised controlled trials (6923 participants), six for cardiac surgery (3359 participants) and seven for thoracic
surgery (3564 participants). The evidence is current to May 2014. No study evaluated fondaparinux, the new oral direct thrombin or
direct factor Xa inhibitors, or caval filters. Data could not be combined because of the different comparisons and the lack of data. Data
for clinically relevant outcomes such as pulmonary embolism (blockage of one or more arteries of the lung) or major bleeding were
often lacking. In cardiac surgery, symptomatic venous thromboembolism occurred in 71 out of 3040 participants from three studies. In
a study of 2551 participants, representing 85% of the review population in cardiac surgery, the combination of unfractionated heparin
with intermittent pneumatic compression was associated with an important reduction of symptomatic venous thromboembolism
compared to unfractionated heparin alone. Major (important) bleeding was reported in one study only, and the best estimate was that
bleedings occurred seven times more often in participants on vitamin K antagonists compared to participants on platelet inhibitors,
but the true estimate may lay between one and a half to 30. In thoracic surgery, symptomatic venous thromboembolism occurred in 15
out of 2890 participants from six studies. Combined analysis could not be performed, but the largest study evaluating unfractionated
heparin versus an inactive control did not show a benefit in terms of reduced occurrence of symptomatic venous thromboembolism.
Major bleeding was reported in two studies that did not find significantly different rates between fixed-dose and weight-adjusted low
molecular weight heparin (2.7% versus 8.1%) and between unfractionated heparin and low molecular weight heparin (6% and 4%).
Quality of the evidence
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Overall, the evidence on the use of thromboprophylaxis in cardiac and thoracic surgery appeared to be scarce, so we are very uncertain
about the benefit-to-risk balance. All studies had major study design flaws and most lacked a placebo or no treatment control group.
We typically graded the quality of the overall body of evidence for the various outcomes and comparisons as low, due to imprecise
estimates of effect and risk of bias. Our data suggest that thromboprophylaxis cannot be suggested for all patients undergoing these
types of surgery, but should rather be considered case-by-case based on the individual risk of venous thromboembolism and bleeding.
B A C K G R O U N D
Description of the condition
Venous thromboembolism (VTE), that is deep vein thrombo-
sis (DVT) and pulmonary embolism (PE), represents a common
complication in patients undergoing surgery, with an incidence
of objectively confirmed postoperative VTE of 10% up to 60%
in the absence of any perioperative thromboprophylaxis (Geerts
2008). Postoperative VTE requires long-term (three to six months
or longer) anticoagulant treatment, which decreases the quality of
life and exposes the patient to the risk of bleeding (Gangireddy
2007; Geerts 2008). In addition, postoperative VTEmay prolong
the length of hospital stay, with consequent additional costs. The
increase in morbidity and mortality associated with postoperative
VTE is particularly challenging among patients with cancer, who
have twice the risk of postoperativeVTE andmore than three times
the risk of fatal PE than non-cancer patients for similar procedures
(Gangireddy 2007; Geerts 2008; Kakkar 2009; White 2003).
The exact incidence of postoperative VTE after thoracic surgery
remains unclear, with the observed estimates ranging from 0.4%
to 51% forDVT and from less than 1% to 5% for PE, about 2% of
the PE cases being fatal (Agnelli 2006; Gangireddy 2007; Jackman
1978; Kalweit 1994; Ljungstrom 1985; Mason 2006; Nagahiro
2004; Sugarbaker 2004; White 2003). The large variation in the
reported incidences likely depends on the type of underlying (co-
morbid) conditions and the diagnostic test used, as well as on the
use and type of thromboprophylaxis in the postoperative period.
The rate of VTE following cardiac surgery is even more contro-
versial since most of the data come from retrospective series with
several methodological limitations (Geerts 2008). Furthermore,
the use of systemic heparin anticoagulation in most cardiac opera-
tions and the administration of antiplatelet drugs or oral anticoag-
ulation after surgery hamper a precise estimation of postoperative
VTE in this setting. Three prospective studies in patients undergo-
ing coronary artery bypass grafting reported postoperative asymp-
tomatic DVT in 16% to 48% of cases and the involvement of the
proximal veins in 3% of the cases (Ambrosetti 2004; Goldhaber
1995; Reis 1991). Symptomatic VTE after cardiac surgery seems
to occur less often, with rates between 0.5% and 3% (Ambrosetti
2004; DeLaria 1991; Gillinov 1992; Goldhaber 1995; Hannan
2003; Josa 1993).
Description of the intervention
Currently available drugs for the prevention of postoperative VTE
are unfractionated heparin (UFH), low molecular weight heparin
(LMWH), and fondaparinux, with the new orally available direct
thrombin and factor Xa inhibitors being under extensive evalu-
ation in phase III clinical studies. In patients with an estimated
high risk of bleeding, a valid option for the prophylaxis of post-
operative VTE is represented by mechanical interventions, which
comprise intermittent pneumatic compression (IPC) devices and
graded elastic compression stockings (Geerts 2008).
Why it is important to do this review
Thromboprophylaxis has been shown to be highly effective in
most hospitalised patients (Geerts 2008), although in some pa-
tient groups the evidence remains scarce and the benefit-to-risk
ratio of thromboprophylaxis is unclear (Bani-Hani 2008; Geerts
2008; Ramos 2008). The provision of effective thromboprophy-
laxis in patients undergoing thoracic or cardiac surgery has the
potential to prevent the significant clinical sequelae of postoper-
ative VTE, particularly in high-risk subgroups of patients such
as those with cancer disease (Agnelli 2006; Collins 1988; Mason
2006; Nagahiro 2004; Sugarbaker 2004). Patients receiving tho-
racic surgery may develop VTE long after the operation (Agnelli
2006; Mason 2006). In a cohort of patients undergoing pneu-
monectomy for cancer, the incidence of VTE peaked seven days
after the operation, whenmost of the patients had already been dis-
charged from the hospital (Mason 2006). Similarly in the @RIS-
TOS study, a prospective observational study of 2373 patients
undergoing oncological surgery, 40% of postoperative VTEs oc-
curred later than 21 days after surgery (Agnelli 2006). Prolonged
thromboprophylaxis after thoracic surgery may offer advantages,
as in other types of surgery (Bergqvist 2002; Geerts 2008; Kakkar
2010), however this has to be balanced against the associated risks
of bleeding (Agnelli 2006; Geerts 2008). People affected by the
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results of this review include adult patients undergoing cardiac or
thoracic surgery as well as healthcare personnel involved in the
therapeutic care of these patients.
O B J E C T I V E S
To assess the effects of primary thromboprophylaxis on the inci-
dence of symptomatic VTE and major bleeding in patients un-
dergoing cardiac or thoracic surgery.
We followed an in-house generated standard protocol for the def-
inition of outcomes, searches, ’Risk of bias’ assessments, data col-
lection, and statistical analyses. The description of the methods
will therefore (partly) overlap with our previous reviews in this
field (Di Nisio 2012a; Di Nisio 2014).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised and quasi-randomised trials were eligible.
Types of participants
We included participants over 18 years of age undergoing cardiac
or thoracic surgery. We evaluated four main groups of patients un-
dergoing surgery: open cardiac surgery, open lung surgery, thora-
coscopic cardiac surgery, and thoracoscopic lung surgery patients.
We excluded studies on thoracic surgery for oesophageal problems,
thoracic sympathectomy, non-lung thoracic surgery, and thoracic
surgery for aortic problems.
Types of interventions
Interventions included any oral or parenteral anticoagulant (for
example UFH, LMWH, fondaparinux, dermatan sulphate, direct
thrombin, or factor Xa inhibitors), mechanical intervention (for
example, sequential compression device or graded elastic compres-
sion stockings), or cava filters.
Comparison interventions included either an inactive control in-
tervention (placebo, no treatment, standard care) or an active con-
trol intervention (a different scheme or regimen of the same in-
tervention, a different pharmacological type of prophylaxis, a dif-
ferent type of non-pharmacological prophylaxis).
We recorded the dose, regimen, anddurationof oral and parenteral
anticoagulants.
We excluded studies if the intervention was not used for primary
prophylaxis of VTE.
Types of outcome measures
Primary outcomes
The main effectiveness outcome was symptomatic VTE (that is
symptomatic DVT, symptomatic PE, or both), which is typi-
cally objectively verified bymeans of Doppler (compression) ultra-
sonography or ascending bilateral venography for (proximal and
distal) DVT, and spiral computed tomography, ventilation/perfu-
sion lung scan, pulmonary angiography, or autopsy for PE.
The main safety outcome was major bleeding, typically defined as
overt bleeding associated with a fall in haemoglobin of 2 g/dL or
more, or leading to a transfusion of two ormore units of packed red
blood cells or whole blood, or bleeding that occurs in a critical site
(intracranial, intraspinal, intraocular, pericardial, intra-articular,
intramuscular with compartment syndrome, retroperitoneal), or
contributing to death.
Secondary outcomes
Secondary outcomes included overall VTE (that is symptomatic
and unsuspected VTE), overall mortality, VTE-related mortal-
ity, post-thrombotic syndrome, minor bleeding, heparin-induced
thrombocytopenia, and the number of participants experiencing
any (serious) adverse events. Serious adverse events were defined
as events resulting in participant hospitalisation, prolongation of
hospitalisation, persistent or significant disability, congenital ab-
normality or birth defect of offspring, life-threatening events, or
death.
Search methods for identification of studies
Electronic searches
The Cochrane Peripheral Vascular Diseases Group Trials Search
Co-ordinator (TSC) searched the Specialised Register (last
searched May 2014) and the Cochrane Central Register of Con-
trolled Trials (CENTRAL) (2014, Issue 4), part of the Cochrane
Library, www.cochranelibrary.com/. See Appendix 1 for details of
the search strategy which was used to searchCENTRAL. The Spe-
cialised Register is maintained by the TSC and is constructed from
weekly electronic searches of MEDLINE, EMBASE, CINAHL,
AMED, and through handsearching relevant journals. The full
list of the databases, journals and conference proceedings which
have been searched, as well as the search strategies used are de-
scribed in the Specialised Register section of the Cochrane Periph-
eral Vascular Diseases Group module in the Cochrane Library (
http://www.cochranelibrary.com/).
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The authors searched the following clinical trial registries to iden-
tify ongoing or unpublished trials (last search May 2014):
• www.clinicaltrials.gov;
• www.controlled-trials.com;
• http://apps.who.int/trialsearch/.
We used the combination of the following search terms: “throm-
bosis”, “thoracic surgery”, and “cardiac surgery”.
Searching other resources
We screened the reference lists of relevant identified studies.
One review author screened the following conference proceedings:
• The American Association of Thoracic Surgery (2003 to
2012);
• European Association of Cardio-Thoracic Surgery (1999 to
2012); and
• The International Society of Thrombosis and Haemostasis
(2003 to 2011);
using the following search terms “thoracic”, “cardiac”, “surgery”,
“operation”, “vein thrombosis”, “venous thrombosis”, “embolism”,
and “prophylaxis”.
We included an abstract if adequate information could be obtained
either from the abstract or from personal communication.
Data collection and analysis
Selection of studies
Two review authors (MdN and FP) independently reviewed titles
and abstracts from the searches to determine whether the inclusion
criteria were satisfied. Any disagreements were resolved through
discussion between the review authors. The review authors were
not blinded to the journal, institution, or results of the study. We
applied no language restrictions. We reassessed studies with in-
sufficient information if additional information became available
from the authors. We documented reasons for excluding studies.
Data extraction and management
Two review authors (MdN and FP) independently extracted the
data from the included studies on standardised forms and resolved
any disagreements by consensus or by involvement of a third re-
view author (AR). Collected information included methodolog-
ical quality, quality of reporting (the reporting of primary out-
comes and sample size calculations), characteristics of participants
participating in the study, characteristics of the intervention and
control groups, and outcome characteristics of every group of par-
ticipants. Whenever possible, we extracted results from an inten-
tion-to-treat analysis. If effect sizes could not be calculated, we
contacted the authors for additional data.
Assessment of risk of bias in included studies
Two review authors independently assessed the methods of ran-
domisation, allocation, blinding, adequacy of analyses, and com-
pleteness of reporting using previously described definitions (Juni
2001; Rutjes 2009). We resolved disagreements by consensus.
We assessed two components of randomisation: generation of al-
location sequences and concealment of allocation. We considered
generation of an allocation sequence at low risk of bias if it resulted
in an unpredictable allocation schedule. Mechanisms considered
adequate included random-number tables, computer-generated
random numbers, minimisation, coin tossing, shuffling cards, and
drawing lots. We considered trials using an unpredictable alloca-
tion sequence to be randomised. We considered trials using poten-
tially predictable allocationmechanisms, such as alternation or the
allocation of participants according to date of birth, to be quasi-
randomised and at high risk of bias.
We considered concealment of allocation at low risk of bias if
participants and investigators responsible for participant selec-
tion were unable to suspect before allocation which treatment
was next.Methods considered adequate included central randomi-
sation; pharmacy-controlled randomisation using identical pre-
numbered containers; and sequentially numbered, sealed, opaque
envelopes.
We considered blinding of patients and therapists adequate if ex-
perimental and control preparations were explicitly described as
indistinguishable or if a double-dummy technique was used. We
considered outcome assessors blinded if this was explicitly men-
tioned by the investigators.
We considered analyses to be at low risk of bias if all randomised
participants were included in the analysis according to the inten-
tion-to-treat principle.
We classified the item ’free of selective reporting’ as at low risk of
bias if we had both the protocol and the full report of a given study,
where the full report presented results for all outcomes listed in the
protocol.We classified a study at high risk of bias if a report did not
present data on all outcomes reported in either the protocol or the
methods section. In the absence of a protocol, we classified as low
risk of bias if the outcomes in the methods section and the results
section matched, and if major participant outcomes expected in
this field of research were addressed (e.g. for the studies involving
pharmacological thromboprophylaxis, any type of bleeding event).
Finally, we planned to use GRADE to describe the quality of the
overall body of evidence (Guyatt 2008; Higgins 2011), defined as
the extent of confidence in the estimates of treatment benefits and
harms.
Measures of treatment effect
Results are shown as a summary risk ratio (RR) for dichotomous
variables and we determined the 95% confidence interval (CI) for
each estimate. In the case of statistically significant overall esti-
mates, we also calculated, where appropriate, clinical effect sum-
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mary statistics, such as the number needed to treat to benefit one
patient (NNTB) or the number needed to treat to harm one pa-
tient (NNTH), to express the final results of the review.
Assessment of heterogeneity
Wemeasured heterogeneity of treatment effects between trials us-
ing the Chi2 test and the I2 statistic (Higgins 2003), which de-
scribes the percentage of total variation across trials that is at-
tributable to heterogeneity rather than to chance. I2 values of 25%,
50%, and 75% are typically interpreted as low, moderate, and
high between-trial heterogeneity. We considered the size of trials
included when interpreting the I2 statistic, as the interpretation
depends on this trial characteristic (Rücker 2008).
Assessment of reporting biases
We planned to evaluate biases related to small study size, such
as publication bias, using funnel plots by plotting relative risks
on the vertical axis against their standard errors on the horizontal
axis. We planned to assess asymmetry by the asymmetry coeffi-
cient, the difference in relative risk per unit increase in standard
error (Harbord 2006), which is mainly a surrogate for sample size.
Symmetry would be expected in the absence of any bias related to
small study size. We planned to explore any asymmetry in strati-
fied analyses to investigate the effects of treatment characteristics
and sub-optimal design choices on the magnitude of the effects.
Data synthesis
Patients undergoing cardiac or non-cardiac thoracic surgery differ
in risk profile for bothVTE and adverse effects, therefore we aimed
to analyse and present data in two separate sections. In the main
analyses of each section, we analysed and presented data by strati-
fying for the type of thromboprophylaxis used. We used standard
inverse-variance random-effects meta-analysis to present outcome
data at end of trial (DerSimonian 1986). We performed the data
analysis in RevMan version 5.3 (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
We planned to explore the between-trial heterogeneity by strat-
ifying the main outcomes for the following trial characteristics:
type of lesion operated on (malignant versus benign in non-cardiac
thoracic surgery trials); type of cardiac surgery (coronary artery
bypass grafting versus valve surgery); urgent versus elective pro-
cedure; concealment of allocation (adequate versus inadequate or
unclear); blinding (adequate versus inadequate or unclear); anal-
ysis in accordance with the intention-to-treat principle (yes ver-
sus no or unclear). We planned to use univariate random-effects
meta-regression models (Thompson 1999), to determine whether
treatment effects are affected by these factors.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Our search identified 2039 reports (Figure 1). Following title and
abstract screening, we considered 107 to be potentially eligible.
Following full-text analysis 13 studies met the review inclusion
criteria andwe excluded 76 studies (85 reports) (Excluded studies).
For one study it was not possible to retrieve either the abstract or
the full-text (Ciavarella 1985). Matching of the review inclusion
criteria could not be verified for the studyRajah 1983.We classified
Avidan 2011; Ciavarella 1985; Ranucci 2013, and Rajah 1983
as studies awaiting classification until additional information can
be retrieved from the authors. Four registered trials are ongoing
(Dixon 2013; Meyer 2011; NCT01267305; NCT00789399).
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Figure 1. Study flow diagram.
7Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Twelve randomised controlled trials (RCTs) and one quasi-ran-
domised controlled trial included a total of 6923 participants. The
two larger studies covered 4971 out of 6803 (72%) included par-
ticipants (Le Brigand 1981; Ramos 1996).
Six studies (3359 participants) evaluated the use of thrombo-
prophylaxis in cardiac surgery (Beghi 1993; Goldhaber 1995;
Mirhosseini 2013; Pfisterer 1989; Ramos 1996; Riess 2007).
The thromboprophylaxis evaluated consisted of UFH (Beghi
1993; Riess 2007), UFH with or without aspirin (Mirhosseini
2013), UFH with or without IPC (Ramos 1996), LMWH (Beghi
1993), IPC with or without graded elastic compression stockings
(Goldhaber 1995), vitaminK antagonists (VKAs) (Pfisterer 1989),
and lepirudin (Riess 2007).
Seven studies (3564 participants) evaluated the use of throm-
boprophylaxis in thoracic surgery (Azorin 1997; Dahan 1990;
Gallus 1973; Le Brigand 1981; Marchetti 1983; Rizzi 1987; van
Geloven 1977). The thromboprophylaxis evaluated consisted of
UFH (Dahan 1990; Gallus 1973; Le Brigand 1981; Marchetti
1983; Rizzi 1987; van Geloven 1977), LMWH (Azorin 1997;
Dahan 1990), defibrotide (Rizzi 1987), and VKAs with or with-
out dextran (van Geloven 1977).
Cardiac surgery
Beghi 1993 recruited patients (n = 39) undergoing open car-
diac surgery for myocardial revascularisation (92.3%), atrial myx-
oma (2.6%), or atrial septal defect (5.1%). Participants were ran-
domised to LMWH (parnaparin 3200 IU once daily (od) subcu-
taneous) versus UFH (5000 IU three times daily (tid) subcuta-
neous) starting on the first day after surgery and continuing for
four postoperative days.
Goldhaber 1995 recruited consecutive patients (n = 344) under-
going coronary artery bypass without concomitant valve surgery
or coronary endarterectomy. Participants were randomised to IPC
plus graded elastic compression stockings versus graded elastic
compression stockings alone. Mechanical prophylaxis was started
postoperatively within four hours to more than 24 hours postop-
eratively.
Mirhosseini 2013 recruited patients (n = 120) undergoing elective
off-pump coronary artery bypass graft and randomised them to
aspirin (80 mg daily orally) plus heparin (5000 U unfractionated
heparin every eight hours subcutaneously) versus heparin (5000 U
unfractionated heparin every eight hours subcutaneously) alone.
Study treatments were given from admission to discharge.
Pfisterer 1989 recruited consecutive patients (n = 285) undergoing
aortocoronary vein bypass surgery and randomised them to VKAs
or platelet inhibitors (dipyridamole plus aspirin) for three or 12
months.
Ramos 1996 recruited consecutive patients (n = 2551) who under-
went open heart surgery including coronary artery bypass surgery
(CABG), CABG plus valve replacement, CABG plus left ventri-
cle aneurysmectomy, CABG plus automatic implantable cardiac
defibrillator, valve replacement, shunt repair, and atrial myxoma
resection. Participants were randomised to UFH (5000 IU twice
daily subcutaneous) with or without bilateral IPC. Both mechani-
cal and pharmacological prophylaxis was started immediately after
surgery and continued for four to five days or until participants
were fully ambulatory.
Riess 2007 recruited patients (n = 20) with coronary artery disease
requiring coronary artery bypass grafting with at least two bypass
grafts. Participants were randomised to lepirudin or UFH. Study
treatmentwas started intravenously and continued subcutaneously
from the third day in the lepirudin group and from the second
day in the UFH group.
Thoracic surgery
Azorin 1997 recruited patients (n = 150) undergoing lung cancer
surgery and randomised them to fixed-dose LMWH (nadroparin
3075 IU od subcutaneous) versus weight-adjusted dose LMWH
(nadroparin 4100 IUor 6150 IUbased on theweight). The first in-
jection of LMWHwas given 12 hours before surgery and LMWH
was continued for eight days post-surgery.
Dahan 1990 recruited 18 to 80-year old patients (n = 100), with
body weight 50 kg to 80 kg, undergoing elective lung cancer
surgery and randomised them toUFH or LMWH. The first phase
of the study was double-blinded and included the period from the
day before surgery to two days after the operation. Participants
were randomised to LMWH (nadroparin, 7500 IU subcutaneous,
first injection 12 hours before surgery, second injection 12 hours
after surgery, and then nadroparin 5000 IU subcutaneous od) or
UFH (calciparine with the first injection two hours before surgery,
second injection 12 hours after surgery, and then tid). The sec-
ond phase of the study was open and included the period from
the third to the seventh day after surgery. In this phase partici-
pants received LMWH (nadroparin 10000 IU od subcutaneous)
or UFH (calciparine twice daily with dose adjusted to activated
partial thromboplastin time (aPTT)).
Gallus 1973 recruited patients (n =350) over 40 years old admitted
for elective surgery, or for emergency surgery after fracture of the
femoral neck and medical patients suspected of having myocardial
infarction. Of the total study population only nine (2.6%) partic-
ipants underwent thoracic surgery. Participants were randomised
to UFH (5000 IU tid subcutaneous) versus no UFH. UFH was
started two hours before surgery and then tid beginning eight to
10 hours after the preoperative dose. Treatment was continued
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until the participant was fully mobile.
Le Brigand 1981 recruited patients (n = 2420) of 21 to 70 years
old undergoing thoracic surgery and randomised them to UFH
(5000 IU subcutaneous twice daily) starting before or after surgery
versus no UFH in case of participants with contraindication or
undergoing minor surgical procedures. UFH was continued until
discharge or for 15 to 21 days.
Marchetti 1983 recruited patients (n = 29) with lung cancer who
underwent pneumonectomy (52%) or lobectomy (48%). Partici-
pants were randomised to UFH (5000 IU tid subcutaneous) ver-
sus placebo. The starting time, end, and duration of study throm-
boprophylaxis was not reported.
Rizzi 1987 recruited consecutive patients (n = 184) undergoing
thoracic surgery, which included exploratory thoracotomy, lung
excision for lung cancer, lobectomy, pleurectomy, cancer excision,
or other. Participants were randomised to defibrotide (400 mg
twice daily intravenous) versus UFH (calcium-heparin 5000 IU
tid subcutaneous) starting the day before surgery and continuing
until there was mobility considered sufficient to reduce the risk
of venous stasis (mean of 7.7 days in the group treated with defi-
brotide and 7.8 days in the UFH group).
van Geloven 1977 recruited patients (n = 331) over 40 years
undergoing elective laparotomy, thoracotomy (n = 83, 26%), or
hip replacement. Participants were randomised in a double-blind
fashion to postoperative VKAs, dextran plus postoperative VKAs,
UFH, and UFH plus postoperative VKAs.
Excluded studies
We excluded a total of 76 studies (85 reports) and the reasons
for exclusions were: intervention not used for primary prophy-
laxis of VTE (Acar 1996; Ageno 2001; Altman 1991; Altman
1996; Aramendi 2005; Attaran 2010; Buchanan 2002; Chesebro
1983; Colli 2007; Dale 1977; Dauphin 2008; Dixon 2008; Dong
2011; Dyke 2006; Eitz 2008; Francis 2003; Ghaffari 2011; Gherli
2004;Gohlke 1981;Hassouna 2000;Hayashi 1994;Hering 2005;
Iliuta 2003; Kaiser 1981; Koertke 2000; Koertke 2003; Koertke
2007;Koertke2010;Kuitunen1997; Laffort 2000;Meschengieser
1997; Mirow 2001; Mok 1985; Ovrum 1996; Pappalardo 2006;
Pengo 1997; Pengo 2007; Pogliani 1982; Pogliani 1993; Pruefer
2001; Rafiq 2013; Renda 2007; Saour 1990; Schlitt 2003; Segesser
1992; Starkman 1982; Swiniarska 2009; Torella 2010; Turpie
1988; Turpie 1993; van der Meer 1994; Voith 1997; Walenga
2001; Warkentin 2013), population included various types of
surgery and data were not provided separately for thoracic or car-
diac surgery (Cade 1983; Cade 1987; Di Carlo 1999; DiSerio
1985; Gallus 1993; Hartshorn 1969; Liezorovicz 1991; Samama
1988; Xia 2011), participants included were children (Jensen
2004; Keidan 2004; Monagle 2011; Pessotti 2012), not a RCT
(Haas 2012; Jackaman 1978; Konkle 2001), andmore than one of
the above (Blair 1994; Kawazoe 1990; Körtke 2001; Ljungstrom
1985; Mehta 2007; Montalescot 2000).
Risk of bias in included studies
The risk of bias in the included studies is shown in Figure 2 and
Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The random sequence was adequately generated in three studies
(Ramos 1996; Rizzi 1987; van Geloven 1977), inadequate in one
(Le Brigand 1981), and unclear in the remainder due to poor
reporting (Azorin 1997; Beghi 1993; Dahan 1990; Gallus 1973;
Goldhaber 1995; Marchetti 1983; Mirhosseini 2013; Pfisterer
1989; Riess 2007).
Allocation was inadequate in one (Le Brigand 1981), and un-
clear in the remainder (Azorin 1997; Beghi 1993; Dahan 1990;
Gallus 1973;Goldhaber 1995;Marchetti 1983;Mirhosseini 2013;
Pfisterer 1989; Ramos 1996; Riess 2007; Rizzi 1987; van Geloven
1977). In one of the two largest studies, the quasi-randomised
trial of Le Brigand 1981, allocation was predictable, driven by
operation times, which were influenced by the risk profile of the
participants.
Blinding
Three studies blinded participants and personnel (Mirhosseini
2013; Pfisterer 1989; van Geloven 1977), eight were open (Azorin
1997; Dahan 1990; Gallus 1973; Goldhaber 1995; Le Brigand
1981; Ramos 1996; Riess 2007; Rizzi 1987), and in two blinding
was unclear due to poor reporting (Beghi 1993; Marchetti 1983).
In Dahan 1990, the first phase of the study was double-blinded
while the second part was open-label. Blinding of study outcomes
assessment was unclear in all studies.
Incomplete outcome data
Four studies performed the analysis according to the intention-to-
treat principle (Gallus 1973; Le Brigand 1981; Mirhosseini 2013;
Riess 2007), while in five studies the percentages of participants
randomised and subsequently excluded from the analysis ranged
from1.3% to 12% (Azorin 1997;Goldhaber 1995; Pfisterer 1989;
Ramos 1996; van Geloven 1977). In four studies it was unclear
if all participants enrolled were considered in the analysis (Beghi
1993; Dahan 1990; Marchetti 1983; Rizzi 1987).
Selective reporting
For five studies selective reporting was unclear due to poor re-
porting (Le Brigand 1981; Marchetti 1983; Mirhosseini 2013;
Pfisterer 1989; Ramos 1996). In all other studies all expected out-
comes were reported.
Other potential sources of bias
We judged two studies to be at high risk of bias as clinically sus-
pected cases of PEwere followed up clinically without an objective
verification of PE, potentially leading to misclassifications for the
occurrence of PE (Dahan 1990; Le Brigand 1981). In three studies
it was not reported whether all clinically suspected cases of VTE
were systematically verified by objective testing (Pfisterer 1989;
Riess 2007; van Geloven 1977). In addition to the verification
method of VTE, we verified if participant inclusion was consec-
utive and whether risk factors for VTE were reported. Only four
studies reported that inclusion was done consecutively (Goldhaber
1995; Pfisterer 1989; Ramos 1996; Rizzi 1987). In the remainder,
the representativeness of the study population for the respective
surgical populations seen in practice remained unclear. In nine
studies participant characteristics and risk factors forVTEwere not
described or poorly reported so that the applicability of the find-
ings could not be interpreted (Beghi 1993; Dahan 1990; Gallus
1973; Marchetti 1983; Mirhosseini 2013; Pfisterer 1989; Ramos
1996; Riess 2007; van Geloven 1977).
Effects of interventions
As none of the trials could be statistically combined with another
trial, we have presented estimates of effect on a trial level and no
stratified analysis or funnel plot explorations were possible.
Cardiac surgery
We identified four studies evaluating pharmacological throm-
boprophylaxis versus inactive or active control (Beghi 1993;
Mirhosseini 2013; Pfisterer 1989; Riess 2007), and two evaluating
the impact of mechanical interventions on patient-relevant out-
comes (Goldhaber 1995; Ramos 1996).
Primary outcomes
The effect of UFH versus LMWHon symptomatic VTE was eval-
uated in the small study of Beghi and colleagues (Beghi 1993), who
reported no cases of VTE in either trial arm (Analysis 1.1). The
effect of mechanical interventions on symptomatic VTE was eval-
uated in two studies, which reported a total number of 71 events
in 2881 participants (Goldhaber 1995; Ramos 1996; Analysis 1.2;
Analysis 1.3). Goldhaber 1995 observed one case of symptomatic
VTE both in participants with IPC plus graded elastic compres-
sion stockings and in those with graded elastic compression stock-
ings. In Ramos 1996, the combination of UFH with IPC was as-
sociated with a significant 61% reduction of symptomatic VTE
compared to UFH alone (1.5% versus 4.0%; RR 0.39; 95% CI
0.23 to 0.64, P value = 0.0002, NNTB 40; 95% CI 26 to 83).
In Mirhosseini 2013, there were no PEs in the UFH group nor in
the UFH plus aspirin group (Analysis 1.4).
Major bleeding events were only reported in the study Pfisterer
1989, where VKAswere associated with a significantly higher inci-
dence of major bleeds relative to platelet inhibitors (11.3% versus
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1.6%, RR 7.06; 95% CI 1.64 to 30.40, P value = 0.009, NNTH
11; 95% CI 6 to 27; Analysis 3.1).
Secondary outcomes
None of the studies reported on VTE-related mortality, post-
thrombotic syndrome, heparin-induced thrombocytopenia, or se-
rious adverse events. In Riess 2007, we did not consider the inci-
dentally reported PE (n = 1) in the lepirudin group nor the throm-
boembolic events (n = 0) in the UFH group as outcome data.
In Mirhosseini 2013 there were significantly fewer unsuspected
DVTs in theUFH plus aspirin group compared to theUFH group
(3.3% versus 16.6%, RR 0.20; 95% CI 0.05 to 0.87). In Pfisterer
1989, overall VTE was not significantly different between VKAs
and platelet inhibitors (0% versus 3.2%; RR 0.11; 95% CI 0.01
to 2.06). In Beghi 1993, a zero count was reported in both trial
arms so that the RR could not be estimated. The effect of me-
chanical interventions on overall VTE was assessed in Goldhaber
1995, who reported that the event rate was comparable between
IPC plus graded elastic compression stockings versus graded elas-
tic compression stockings alone (19% versus 22%, RR 0.87; 95%
CI 0.57 to 1.34).
Regarding the remaining secondary outcomes, none of the studies
showed any statistically significant difference between thrombo-
prophylaxis and control interventions (Data and analyses).
Overall mortality was only reported in the study Pfisterer 1989,
where VKAs were associated with a non-significant four-fold risk
increase compared to platelet inhibitors (6.5% versus 1.6%; RR
4.03; 95% CI 0.87 to 18.61).
The effect of pharmacological thromboprophylaxis on minor
bleeding was evaluated by Beghi 1993 and Pfisterer 1989. Beghi
1993 reported 4/19 and 0/20 minor bleeds in the UFH and
LMWH groups, respectively. Pfisterer 1989 found no significant
differences in minor bleeding between VKAs and platelet in-
hibitors (RR 2.02; 95% CI 0.52 to 7.88). We identified no study
that evaluated the effect of mechanical interventions on minor
bleeding.
The effect of pharmacological thromboprophylaxis on adverse
events was reported in Pfisterer 1989, where VKAs were associated
with a 70% lower incidence of adverse events compared to platelet
inhibitors (RR 0.30; 95% CI 0.13 to 0.73).
Thoracic surgery
We identified seven studies evaluating pharmacological thrombo-
prophylaxis versus inactive or active control (Azorin 1997; Dahan
1990; Gallus 1973; Le Brigand 1981;Marchetti 1983; Rizzi 1987;
van Geloven 1977). None of the studies evaluated the impact of
mechanical interventions.
Primary outcomes
None of the studies showed any statistically significant difference
between pharmacological thromboprophylaxis on any of the pri-
mary outcomes.
Across the six studies reporting on symptomatic VTEs in 2890
participants undergoing thoracic surgery, 15 symptomatic VTEs
occurred in total (Azorin 1997; Dahan 1990; Gallus 1973; Le
Brigand 1981; Marchetti 1983; Rizzi 1987).
Three studies evaluated the impact of heparin versus inactive
control on symptomatic VTE (Gallus 1973; Le Brigand 1981;
Marchetti 1983), but the risk ratio could not be estimated in two
of these, because of zero event rates in both trial arms (Gallus 1973;
Marchetti 1983; Analysis 2.1). The third study by Le Brigand
1981 could not detect a statistically significant difference in symp-
tomatic VTE between UFH and inactive control treatment (0.7%
versus 0%; RR 6.71; 95% CI 0.40 to 112.65). Three additional
studies studied the effect of heparin versus active control on symp-
tomatic VTE (Azorin 1997; Dahan 1990; Rizzi 1987; Analysis
2.2; Analysis 2.3; Analysis 2.4). In the small study by Rizzi 1987,
there were two symptomatic VTEs in the UFH group and none
with defibrotide, while no VTE was observed in either trial arm
in the studies of Azorin 1997 and Dahan 1990.
Major bleeding was reported in two studies (Azorin 1997; Dahan
1990), which found no difference between the experimental and
control groups. In the study Azorin 1997, major bleeds occurred
in 2.7% of participants receiving fixed-dose LMWH compared
to 8.1% in those on weight-adjusted LMWH (RR 0.33; 95% CI
0.07 to 1.60). In Dahan 1990, these occurred in 6% in the UFH
and in 4% in the LMWH groups (RR 1.50; 95%CI 0.26 to 8.60).
Secondary outcomes
None of the studies reported on symptomatic PE, overall or VTE-
related mortality, post-thrombotic syndrome, or heparin-induced
thrombocytopenia. None of the studies showed any statistically
significant difference between pharmacological thromboprophy-
laxis on any of the remaining secondary outcomes (Data and
analyses). Four studies reported on overall VTE (Azorin 1997;
Dahan 1990; Gallus 1973; van Geloven 1977). In both Gallus
1973 andDahan 1990, there were no events in the intervention or
control group. Azorin 1997 reported one VTE in 74 participants
in the fixed-dose LMWH group versus none in the weight-ad-
justed dose LMWH group (RR 3.00; 95% CI 0.12 to 72.47). No
difference in overall VTE was observed in the study van Geloven
1977, with three VTEs in 19 participants in the UFH and five
VTEs in 22 participants in the VKA groups (RR 0.69; 95% CI
0.19 to 2.53).
Minor bleeding was reported in two studies (Azorin 1997; Dahan
1990). In Dahan 1990, there were eight out of 50 versus two out
of 50 events in the UFH and LMWH groups, respectively (RR
4.00; 95% CI 0.89 to 17.91). Similarly, no difference in minor
bleeding was reported by Azorin 1997 (RR 0.50; 95% CI 0.05 to
5.40).
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Azorin 1997 was the only study in thoracic surgery that reported
on serious adverse events and adverse events. There were two out
of 74 versus three out of 74 serious adverse events in the fixed-dose
and weight-adjusted dose LMWH groups, respectively (RR 0.67;
95% CI 0.11 to 3.87), and three adverse events in both groups
(RR 1.00; 95% CI 0.21 to 4.79).
D I S C U S S I O N
Summary of main results
The evidence about the efficacy and safety of thromboprophylaxis
in cardiac and thoracic surgery is limited to few studies with sub-
stantialmethodological problems.Overall, unfractionated heparin
(UFH) was the form of thromboprophylaxis most often evaluated
in both types of surgery, whereas data on other types thrombo-
prophylaxis were scarce or not available as for fondaparinux, the
new oral anticoagulants, or caval filters. In cardiac surgery, the
combination of intermittent pneumatic compression (IPC) and
UFH seemed to significantly reduce symptomatic venous throm-
boembolism (VTE) compared to UFH alone, as demonstrated in
a single study of low quality. None of the study designs, how-
ever, allowed us to evaluate if UFH itself is associated with an in-
creased benefit or harm. In thoracic surgery, even the largest study,
Le Brigand 1981, was underpowered to show a significant effect
of UFH versus inactive control on symptomatic VTE (RR 6.71;
95% CI 0.40 to 112.65). No significant differences between any
prophylactic regimen and control could be demonstrated for any
of the outcomes in thoracic surgery. In both type of operations,
the absolute rate of events was low, resulting in broad confidence
intervals around the estimates. Furthermore, although the studies
typically addressed some type of bleeding outcome in their reports,
the definition of major bleeding was addressed in three studies out
of 13 only, which further hampered the risk-benefit evaluations.
In conclusion, there is currently no evidence to recommend rou-
tine thromboprophylaxis in patients undergoing cardiac or tho-
racic surgery. No definite conclusion can be made about the ef-
fectiveness of IPC, as future studies are likely to have a substantial
impact on our confidence in the estimate of effect andmay change
the estimate.
Overall completeness and applicability of
evidence
For both cardiac and thoracic surgery, one study contributed to
more than two-thirds of the population included in the review for
that type of surgery (Ramos 1996 and Le Brigand 1981, respec-
tively). In Ramos 1996, poor reporting was an obstacle to a proper
evaluation of study quality and no data were provided for major
efficacy and safety outcomes such as deep vein thrombosis (DVT),
major bleeding, or overall mortality. Interestingly, the authors re-
ported a relatively high incidence of symptomatic pulmonary em-
bolism (PE) (2.7%), which was possibly explained by the short du-
ration of thromboprophylaxis after surgery. Le Brigand 1981 had
major methodological limitations, potentially introducing signif-
icant bias. The incomplete outcome reporting within and across
trials hampered a comprehensive assessment of the safety and ef-
fectiveness of the treatments under evaluation. As an example, of
nine studies reporting on symptomatic VTE only two provided
data on major bleeding events. Additionally, it was often unclear
how systematically these endpoints were searched for and verified.
The secondary outcomes as formulated for this review were in-
frequently reported, and none of the trials reported all secondary
outcomes of interest. The reporting of patient characteristics and
the risk profile for the development of thromboembolic events was
poorly or not described in the studies, so that we were unable to
interpret the general applicability of the research findings. We ob-
served a considerable variation in the event rates of symptomatic
VTE across the studies, which could be the result of the lack of a
systematic and objective verification of suspected cases, differences
in the duration of thromboprophylaxis, characteristics of the study
populations such as the type of cardiac or thoracic surgery, or the
presence of concomitant VTE risk factors. Only one randomised
controlled trial (RCT) in cardiac surgery (Pfisterer 1989), and two
in thoracic surgery (Azorin 1997; Dahan 1990), reported on ma-
jor bleeding. Pfisterer 1989 randomised participants to vitamin K
antagonists or platelet inhibitors, which represent unusual types of
prophylaxis for VTE in the surgical setting. Both Azorin 1997 and
Dahan 1990 suggested a high risk of major bleeding with rates up
to 8% with heparin prophylaxis. All three studies lacked a control
group with no pharmacological prophylaxis, which hampered any
assessment of the residual risk of major bleeding without inter-
vention.
Quality of the evidence
Themethodological quality of the included studies was low to very
low (Higgins 2011). Poor reporting did not allow proper scoring
of relevant study design features such as sequence generation and
allocation concealment in the majority of included studies and
we classified none of the studies as at an overall low risk of bias
(Figure 2; Figure 3). Concerning the quality of the evidence at the
outcome level, we downgraded all outcomes in all comparisons
for methodological shortcomings. In addition, except for one out-
come in one comparison, estimates were imprecise with wide con-
fidence intervals including both negligible, appreciable beneficial,
and appreciable harmful effects (Ramos 1996). The only precise
effect was found for IPC on symptomatic VTE, where the upper
limit of the confidence interval still represented an appreciable
benefit, but we downgraded the quality for this outcome to low
confidence in the estimate of the effect because of methodological
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shortcomings (Ramos 1996). There was not enough evidence to
judge publication bias or the risk of bias for incomplete outcome
reporting at the trial level. The directness or applicability of the
evidence was generally unclear, as described in the previous sec-
tion.
Potential biases in the review process
Our systematic approach to searching, study selection, and data
extraction followed that of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). In addition, we used an
in-house made protocol for classification of the of methodological
items, which some of our authors have applied in their previous re-
search (Di Nisio 2012a; Rutjes 2009). Our search was sufficiently
broad and as we did not apply language restrictions, therefore we
feel confident we have identified all or at least most published re-
ports. We cannot exclude the possibility of having missed unpub-
lished work.
The main limitation of this review is that it identified few studies
that were adequately powered and none of the studies could be
statistically pooled.The included studies did not compare the same
type of treatments for the same study outcomes and, where they
did, they still could not be combined because of the zero event
counts in both trial arms (Azorin 1997; Beghi 1993; Dahan 1990;
Gallus 1973; Marchetti 1983). The ’no difference’ findings for a
specific outcomemay thus be the result of the insufficient power of
the analysis to show a difference between treatment groups as well
as the absence of a true effect. Due to the paucity of data, it was
impossible to conduct stratified analyses for the primary efficacy
outcomes to evaluate the interaction of trial characteristics with
treatment effects.
Agreements and disagreements with other
studies or reviews
The evidence on the use of thromboprophylaxis in patients un-
dergoing cardiac and thoracic surgery was recently summarised
and discussed in the guidelines of the American College of Chest
Physicians (Gould 2012). In that review only two studies were
included for both cardiac and thoracic surgery. Despite the fact
that our search strategy identified 10 additional studies, the con-
clusions are similar.
In a previous Cochrane review, Akl and colleagues summarised the
evidence for perioperative thromboprophylaxis in patients with
cancer from 16 studies including 11,847 participants (Akl 2011).
This review focused on LMWH and UFH as interventions and
included only cancer patients undergoing any type of surgery,
so that only one study appears in both reviews (Dahan 1990).
Akl 2011 concluded that no difference could be found between
perioperative thromboprophylaxis with LMWH or UFH in terms
of mortality and embolic outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When deciding whether to use primary antithrombotic prophy-
laxis in patients undergoing cardiac or thoracic surgery, a clinician
needs to determine the patients’ baseline risk of venous throm-
boembolism (VTE) and weigh the magnitude of benefit on clini-
cally major endpoints against the risk of bleeding. Co-morbidities
predisposing to bleeding, which often represent an exclusion cri-
terion in randomised controlled studies on anticoagulants, might
result in higher rates of major bleeding and limit the use of throm-
boprophylaxis in ’real life’. The review data appear too preliminary
to clearly establish the risk-to-benefit ratio of thromboprophy-
laxis, suggesting caution in the adoption of any pharmacological
thromboprophylaxis. In the absence of evidence, mechanical types
of prophylaxis may be suggested for cardiac and thoracic surgery
and pharmacological prophylaxis may be considered in patients
with an estimated lower risk of bleeding and higher risk of VTE
(Gould 2012).
Implications for research
Additional randomised studies are needed to clearly establish the
risk-to-benefit ratio of pharmacological and non-pharmacologi-
cal prophylaxis. Studies have to report on clinically relevant out-
comes such as symptomatic pulmonary embolism (PE) and major
bleeding, while possibly addressing the patient preferences and the
effects on quality of life. As well as the type of prophylaxis and
its starting time (postoperative versus preoperative), the duration
should be studied as some preliminary data suggest a persisting
risk of VTE long after the operation (Agnelli 2006; Mason 2006).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Azorin 1997
Methods RCT, open, prospective, multicentre
Participants Patients (n = 150 randomised, 148 treated) undergoing lung cancer surgery
Age (± SD): 56.8 (± 1.4) in the fixed-dose LMWH and 58.9 (± 1.3) in the adjusted dose;
males were 86.5% and 82.4%, respectively
Interventions - Fixed-dose LMWH, nadroparin (3075 IU Anti-Xa subcutaneous injection)
- Adjusted-dose LMWH, nadroparin (4100 IU/6150 IUAnti-Xa subcutaneous injection
in participants with body weight 40 kg to 70 kg/71 kg to 110 kg)
The first injection of LMWH was given 12 hours before surgery and LMWH was
continued for 8 days post-surgery
Outcomes DVT, PE, major bleeding, overall VTE, minor bleeding, SAE and AE
DVTwas confirmed byDoppler compression ultrasonography. Bilateral ascending phle-
bography was used to confirm positive findings on ultrasonography. PE was confirmed
by pulmonary angiography
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not re-
ported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 participants enrolled (1.3%) not included in
the analysis
Selective reporting (reporting bias) Low risk Study not registered. No published protocol.
All outcomes mentioned in the methods section
were addressed in the results section
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Azorin 1997 (Continued)
Other bias Unclear risk Participant characteristics are not reported. Un-
clear if participants were consecutively included
Beghi 1993
Methods RCT
Participants Patients (n = 39) undergoing open cardiac surgery, 20 were randomised to the LMWH
group and 19 to the calcium-heparin group. Mean age was 60.2 (± 1.9) years in LMWH
and 60.5 (± 2.4) years in calcium-heparin; 31/39 (79%) were males. One or more
risk factors for DVT were reported in 100% of LMWH and 72% of calcium-heparin
patients. Indication for surgery: myocardial revascularisation (92.3%), atrial myxoma
(2.6%), atrial septal defect (5.1%)
Interventions - LMWH, parnaparin (3200 IU od subcutaneous)
- Calcium-heparin (5000 IU tid subcutaneous)
Thromboprophylaxis was started on the first day after surgery and continued for 4
postoperative days
Outcomes Symptomatic and asymptomatic DVT. Physical examination and colour Doppler ultra-
sonography were used to diagnose DVT
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported if participants and personnel were blinded to study
treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear if all participants enrolled were subsequently con-
sidered in the analysis
Selective reporting (reporting bias) Low risk Study not registered. No published protocol. All outcomes men-
tioned in the methods section were addressed in the results sec-
tion
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Beghi 1993 (Continued)
Other bias Unclear risk Participant characteristics are not reported. Unclear if partici-
pants were consecutively included
Dahan 1990
Methods Prospective, multicentre, randomised study
Participants Of 100 patients undergoing elective lung cancer surgery, 50 were randomised to the
LMWH group and 50 to the UFH group. Mean age was 59 years; males: 92%
Interventions First phase (double-blinded) from the day before surgery to 2 days after the operation:
- LMWH, nadroparin (7500 IU subcutaneous), first injection 12 hours before surgery,
second injection 12 hours after surgery, and then nadroparin (5000 IU subcutaneous)
od
- UFH, calciparine, first injection 2 hours before surgery, second injection 12 hours after
surgery, and then tid
Second phase (open-label) from the 3rd to the 7th day after surgery
- LMWH, nadroparin (10000 IU od subcutaneous)
- UFH, calciparine twice daily with dose adjusted to aPTT
Outcomes DVT, major and minor bleeding, clinical symptoms of PE. DVT was verified by 125I
fibrinogen test and confirmed by bilateral phlebography if the former test was positive
Notes Antiplatelet agents and oral anticoagulants were forbidden from 10 days before to 7
days after surgery. From recovery to discharge from the surgical ward, participants wore
venous support stockings
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported. Quote: “randomized study”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The first phase of the study (up to day
2 post-surgery) was double-blinded, the
second phase was open. The outcomes
were evaluated at end of the second phase,
which may have introduced performance
bias.Quotes: “partially double blind”; “first
phase conducted double blind”; “second
open phase was conducted”
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Dahan 1990 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is not clear nor reported if all included
participants completed follow-up nor the
exact duration of the observation period
Selective reporting (reporting bias) Low risk Study not registered. No published proto-
col. All outcomes mentioned in the meth-
ods section were addressed in the results
section
Other bias High risk Participant characteristics and risk factors
for VTE are poorly reported. It is not re-
ported if clinically suspected PE was objec-
tively confirmed. The timing of outcome
assessment was not reported and it was un-
clear if all participants completed follow-
up. Due to the very poor quality of report-
ing, we judged the risk to be high
Gallus 1973
Methods RCT
Participants Patients (n = 350) over 40 years old admitted for elective surgery, or for emergency
surgery after fracture of the femoral neck and medical patients suspected of having
myocardial infarction. Mean age and gender were not reported separately for thoracic
surgery patients, which represented less than 3% of the study population
Interventions - UFH 5000 IU sc 2 hours before surgery and then tid starting 8 to 10 hours after the
preoperative dose. Treatment was continued until the participant was fully mobile
- Control: no UFH
Outcomes DVT and bleeding. DVTwas objectively verified by 125I-fibrinogen scanning performed
before surgery, within 4 hours of the end of surgery, and then daily until fully mobile
or discharge. Venography was performed if the 125I-fibrinogen scanning suggested the
presence of thrombosis of the popliteal or femoral veins
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not reported: “...were
randomized separately”
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Gallus 1973 (Continued)
Allocation concealment (selection bias) Unclear risk Numbered, sealed envelopes. It remained unclear whether en-
velopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgeons were unaware of study treatment. Participants were
not blinded and it is not reported if the other study personnel
were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included were considered in the analysis
Selective reporting (reporting bias) Low risk Study not registered. No published protocol. All outcomes men-
tioned in the methods section were addressed in the results sec-
tion
Other bias Unclear risk Participant characteristics are not reported. Unclear if partici-
pants were consecutively included
Goldhaber 1995
Methods RCT, multicentre
Participants Consecutive patients (n = 344) undergoing coronary artery bypass without concomitant
valve surgery or coronary endarterectomy. Males: 80% in the IPC plus graded elastic
compression stockings and 89% in graded elastic compression stockings; age: 63.2 (± 9.
7) and 64.3 (± 9.8), respectively
Interventions - IPC (Sequential Compression Device) plus graded elastic compression stockings
- Graded elastic compression stockings
The IPC device delivered compression of 45 mmHg at the ankle, 40 mmHg at the calf,
and 30 mmHg at the thigh. Prophylaxis was started within 4 hours postoperatively in
most participants although in some participants prophylaxis was instituted 12 hours or
more than 24 hours postoperatively
Outcomes Pre-discharge DVT verified by colour Doppler compression ultrasonography on or after
the 4th postoperative day
Notes All participants received aspirin (325 mg/day)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not reported
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Goldhaber 1995 (Continued)
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel is not reported but it is
likely an open study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/344 participants (4%) did not undergo pre-discharge ultra-
sonography
Selective reporting (reporting bias) Low risk Study not registered. No published protocol. All outcomes men-
tioned in the methods section were addressed in the results sec-
tion
Other bias Unclear risk Consecutive series of participants. Participant characteristics in-
completely reported
Le Brigand 1981
Methods Quasi-randomised, single-centre study
Participants Patients (n = 2420) of 21 to 70 years old undergoing thoracic surgery
Interventions - Group A: UFH 5000 IU subcutaneous starting 2 hours and 30 minutes before surgery
and then twice daily
- Group B: UFH 5000 IU subcutaneous starting 24 to 72 hours after surgery then twice
daily
- Control: no UFH because of contraindication or minor surgical procedures
UFH doses were increased after the 4th day to maintain a difference in partial throm-
boplastin time between participant and control between 7 and 14 seconds. UFH was
continued until discharge or for 15 to 21 days
UFH doses were increased postoperatively to therapeutic levels in case of clinically sus-
pected VTE
Outcomes Fatal and non fatal PE. The authors did not report if all suspected cases of PE and/or
DVT underwent objective test confirmation
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Le Brigand 1981 (Continued)
Random sequence generation (selection
bias)
High risk This was a quasi-randomised trial in which
participants were allocated to study treatment
according to the time of operation. However,
the time of surgery was influenced by the pres-
ence or absence of contraindications and the
type of surgical procedure (minor versus ma-
jor)
Allocation concealment (selection bias) High risk The allocation was not concealed but planned
and thus predictable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is not explicitly reported whether person-
nel or participants were blinded but, given the
type of interventions considered, it is likely
that the study was open
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not explicitly reported whether outcome
assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included participants were considered in
the analysis
Selective reporting (reporting bias) Unclear risk Outcomes are not clearly specified in the re-
port and no protocol is available
Other bias High risk Participants in the study treatment groups had
a different prognosis before the surgical pro-
cedure and, accordingly, could have a differ-
ent risk of VTE. Clinically suspected cases of
PE were followed up clinically but it is not re-
ported if they all underwent an objective test
for PE
Marchetti 1983
Methods RCT
Participants Patients (n = 29) with lung cancer. 18 (62%) were males; age between 40 and 62 years;
type of surgery: 15 (52%) pneumonectomy, 14 (48%) lobectomy
Interventions - UFH, calcium-heparin (5000 IU tid subcutaneous)
- Placebo
The duration of thromboprophylaxis is not reported
Outcomes Symptomatic VTE. It is unclear if the suspected cases were objectively verified
Notes -
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Marchetti 1983 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This is a placebo-controlled study, however, it is not reported if
the vials and solutions were indistinguishable
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear if all participants enrolled were subsequently con-
sidered in the analysis
Selective reporting (reporting bias) Unclear risk Outcomes are not clearly specified a priori and the protocol is
not available
Other bias Unclear risk Participant characteristics are not reported. Unclear if partici-
pants were consecutively included
Mirhosseini 2013
Methods Prospective, double-blind, RCT
Participants Patients (n = 120) undergoing elective off-pump coronary artery bypass graft. Mean
age: 63.41 ± 10.71 heparin group and 60.80 ± 10.64 heparin plus aspirin group. Male/
female: 42/18 and 41/19, respectively
Interventions Intervention: aspirin (80 mg daily orally) plus heparin (5000 U unfractionated heparin
every 8 hours subcutaneously)
Control: heparin (5000 U unfractionated heparin every 8 hours subcutaneously)
Study treatments were given from admission to discharge
Outcomes Deep vein thrombosis, bleeding, and pulmonary embolism
All participants underwent right and left leg venous ultrasound examination during
hospitalisation
Notes Conflict of interest: none declared
Risk of bias
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Mirhosseini 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not reported. Quote:
“The patients were randomly assigned into two
groups”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported.
Quote: “The patients were randomly assigned into
two groups”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The nurse (observer) who took themedicine
to the patients (participants) and the patients them-
selves were blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment not reported.Quote:
“Ultrasonography was performed by an experienced
and expert physician”
Incomplete outcome data (attrition bias)
All outcomes
Low risk From Table 3 (Mirhosseini 2013), it appears that all
participants randomisedwere included in the analysis
Selective reporting (reporting bias) Unclear risk Outcomes are not clearly specified in the methods.
Quote: “...post-operation early complications such
as bleeding and pulmonary embolism (PE), were
recorded.”
Other bias Unclear risk It is unclear if participants were consecutively in-
cluded. Risk factors for VTE are poorly reported
Pfisterer 1989
Methods Prospective, randomised study
Participants Consecutive patients (n = 285) undergoing aortocoronary vein bypass surgery. Mean age
(range): 55 (35 to 75) in the 12-month VKAs, 56 (39 to 75) in the 3-month VKAs, 57
(40 to 69) in the 12-month platelet inhibitors, and 55 (35 to 70) in the 3-month platelet
inhibitors. The percentage of men was 88%, 92%, 87%, and 94% respectively
Interventions - VKAs, phenprocoumon, for 12 months
- VKAs, phenprocoumon, for 3 months followed by placebo for 9 months
Phenprocoumon was started on the first postoperative day and given at doses adjusted
according to prothrombin time
- Platelet inhibitors, dipyridamole, and aspirin, for 12 months
- Platelet inhibitors, dipyridamole, and aspirin, for 3 months followed by placebo for 9
months
Treatment with platelet inhibitors consisted of dipyridamole (200mg twice daily) started
2 days preoperatively and followed by a combination of dipyridamole (200 mg twice
daily) and aspirin (25 mg twice daily) starting on the morning of surgery
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Pfisterer 1989 (Continued)
Outcomes Death, bleeding (major and minor), venous thromboembolism (unclear if symptomatic,
asymptomatic, or both), adverse events
Notes All participants were fully heparinised during extracorporeal circulation with heparin
stopped immediately after bypass. The rate of preoperative treatmentwith anticoagulants
was 39% in the 12-month anticoagulants, 40% in the 3-month anticoagulants, 47%
in the 12-month platelet inhibitors, and 29% in the 3-month platelet inhibitors. The
corresponding rates of preoperative use of platelet inhibitors were 17%, 12%, 15%, and
21%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not reported
Allocation concealment (selection bias) Unclear risk Numbered, sealed envelopes. It remained unclear
whether envelopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 36 out of 289 participants (12%) were excluded from
the final analysis. 2 additional participants were lost to
follow-up
Selective reporting (reporting bias) Unclear risk Outcomes are not clearly listed in the methods and a
protocol was not available
Other bias Unclear risk Participant characteristics and VTE risk factors are not
clearly reported for the treatment groups. The authors
do not report if all clinically suspected cases of VTE
were systematically verified by objective testing
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Ramos 1996
Methods Randomised study
Participants Consecutive patients (n = 2551) who underwent open heart surgery. The type of surgery
included coronary artery bypass surgery (CABG), CABG plus valve replacement, CABG
plus left ventricle aneurysmectomy, CABG plus automatic implantable cardiac defibril-
lator, valve replacement, shunt repair, and atrial myxoma resection. Mean age (± SD):
65 ± 11 in the UFH group and 63 ± 13 in the UFH plus IPC group. Males: 68% and
71%, respectively
Interventions - UFH (5000 IU twice daily subcutaneous)
- UFH (5000 IU twice daily subcutaneous) plus bilateral IPC
Both mechanical and pharmacological prophylaxis was started immediately after surgery
and continued for 4 to 5 days or until participants were fully ambulatory
Outcomes Symptomatic pulmonary embolism objectively verified by ventilation perfusion scans,
pulmonary angiography, and/or autopsy
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using a table of random numbers
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel not reported, but the
study is likely open
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 235 of the 2786 participants randomised (8.4%) were subse-
quently excluded from the analysis
Selective reporting (reporting bias) Unclear risk Apart from symptomatic PE, other outcomes are not reported
and no protocol is available
Other bias Unclear risk Participant characteristics and risk factors for VTE are not re-
ported in detail
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Riess 2007
Methods Randomised study
Participants Patients (n = 20) with coronary artery disease requiring coronary artery bypass grafting
with at least 2 bypass grafts. Mean age (± SD): 55.0 ± 0.6 in the lepirudin group and 59.
0 ± 0.5 in the UFH group
Interventions - Lepirudin (0.25 mg/kg intravenous bolus and 0.2 mg/kg added to cardiopulmonary
bypass priming followed by additional 5 mg lepirudin boluses to maintain lepirudin
concentrations above 4 µg/mL)monitored using the ecarin clotting time.During the first
2 days after operation, anticoagulation was performed with an intravenous and aPTT
adjusted (target range: 45 to 60 seconds) lepirudin infusion (initial dosage 0.05 mg/kg)
. From the third postoperative day lepirudin was given subcutaneously until complete
mobilisation
- UFH (400 IU/kg bolus prior to connection to the cardiopulmonary bypass followed
by additional 5000 IU UFH boluses to maintain an activated clotting time above 400
seconds). After the end of the operation, UFH (4 IU/kg/h intravenous) starting 4 hours
after surgery if the aPTT was below 45 seconds. UFH was increased to 8 IU/kg/h 24
hours later, and 48 hours after the operation UFH (7500 IU twice daily) was given
subcutaneously until complete mobilisation
Outcomes Blood clots within the cardiopulmonary bypass circuits, perioperative blood loss, hae-
matologic values, blood chemistry, coagulation values
Notes After the end of subcutaneous anticoagulation treatment, participants in both groups
received acetylsalicylic acid (100 mg/day)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Open study, but blinding of outcome assessors not specifically
addressed
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants enrolled were subsequently considered in the
analysis
Selective reporting (reporting bias) Low risk Study not registered. No published protocol. All outcomes men-
tioned in the methods section were addressed in the results sec-
tion
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Riess 2007 (Continued)
Other bias Unclear risk Participant characteristics and risk factors for VTE are not re-
ported. It is not reported if all participants with clinically sus-
pected DVT and/or PE were systematically verified by objective
testing
Rizzi 1987
Methods Randomised study
Participants Consecutive patients (n = 184) undergoing thoracic surgery. Males: 79% in the defi-
brotide group and 81% in the UFH group. Type of surgery: exploratory thoracotomy
18% and 15%, lung excision for lung cancer 20% and 24%, lobectomy 33% and 41%,
pleurectomy 13% and 10%, cancer excision 14% and 9%, other 2% and 0%
Interventions - Defibrotide 400 mg twice daily intravenous
- UFH, calcium-heparin 5000 IU tid subcutaneous
Thromboprophylaxis was started the day before surgery and continued until there was
a mobility considered sufficient to reduce the risk of venous stasis (mean of 7.7 days in
the group treated with defibrotide and 7.8 days in the UFH group)
Outcomes Speed of wound repair, symptomatic VTE, bleeding. It is not reported if VTE was
objectively verified
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence was generated with the use of a random list
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear if all participants enrolled were subsequently con-
sidered in the analysis
Selective reporting (reporting bias) Low risk Study not registered. No published protocol. All outcomes men-
tioned in the methods section were addressed in the results sec-
tion
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Rizzi 1987 (Continued)
Other bias Unclear risk Participant characteristics are not reported
van Geloven 1977
Methods Randomised, double-blind study
Participants Patients (n = 331) over 40 years undergoing elective laparotomy, thoracotomy (n = 83,
26%), or hip replacement
Interventions - Postoperative VKAs (Sintrom, acenocoumarol started on the first postoperative day)
plus a placebo dextran infusion (during the operation and 24 hours on the first post-
operative day) plus placebo UFH (twice daily subcutaneous starting 2 hours before the
operation)
- Dextran (500 ml dextran 40 and 500 ml 24 hours later on the first postoperative day)
plus postoperative VKAs (Sintrom, acenocoumarol started on the first postoperative day)
plus placebo UFH (twice daily subcutaneous starting 2 hours before the operation)
- UFH (5000 IU twice daily subcutaneous starting 2 hours before the operation) plus
placebo VKAs (Sintrom, acenocoumarol started on the first postoperative day) plus a
placebo dextran infusion (during the operation and 24 hours on the first postoperative
day)
- UFH (5000 IU twice daily subcutaneous starting 2 hours before the operation) plus
postoperative VKAs (acenocoumarol) plus a placebo dextran infusion (during the oper-
ation and 24 hours on the first postoperative day). UFH was continued for 4 days and
then replaced by placebo
It is not reported how long the study treatments were continued after the operation
Outcomes DVT, PE, blood loss. All participants with a positive 125I fibrinogen uptake scan under-
went a chest X-ray and pulmonary perfusion scintigraphy with 99m Tc-labelled macroag-
gregates of human albumin
Notes The authors report that lower than expected doses of heparin (about 4000 IU twice
daily) were accidentally administered during the first part of the study in the heparin
groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
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van Geloven 1977 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 18 of the 331 participants enrolled (5.4%) were ex-
cluded from the analysis
Selective reporting (reporting bias) Low risk Study not registered. No published protocol. All
outcomes mentioned in the methods section were
addressed in the results section
Other bias Unclear risk Participant characteristics and risk factors for VTE
are not reported. It is not reported if all participants
with clinically suspected DVT and/or PE were sys-
tematically verified by objective testing. Not clear if
participants were consecutively enrolled
AE: adverse events
aPTT: activated partial thromboplastin time
DVT: deep vein thrombosis
IPC: intermittent pneumatic compression
LMWH: low molecular weight heparin
od: once daily
PE: pulmonary embolism
RCT: randomised controlled trial
SAE: serious adverse events
sc: subcutaneous
SD: standard deviation
tid: three times daily
VKA: vitamin K antagonist
VTE: venous thromboembolism
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acar 1996 Intervention not used for primary prophylaxis of VTE
Ageno 2001 Intervention not used for primary prophylaxis of VTE
Altman 1991 Intervention not used for primary prophylaxis of VTE
Altman 1996 Intervention not used for primary prophylaxis of VTE
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(Continued)
Aramendi 2005 Intervention not used for primary prophylaxis of VTE
Attaran 2010 Intervention not used for primary prophylaxis of VTE
Blair 1994 Not a RCT and intervention not used for primary prophylaxis of VTE
Buchanan 2002 Intervention not used for primary prophylaxis of VTE
Cade 1983 Both oesophagus and thoracic lung surgery included and data are not provided separately for thoracic lung
surgery
Cade 1987 Both abdominal and thoracic surgery included and data are not provided separately for thoracic surgery
Chesebro 1983 Intervention not used for primary prophylaxis of VTE
Colli 2007 Intervention not used for primary prophylaxis of VTE
Dale 1977 Intervention not used for primary prophylaxis of VTE
Dauphin 2008 Intervention not used for primary prophylaxis of VTE
Di Carlo 1999 Abdominal, gynaecological, urological, and thoracic surgery included and data not provided separately for
thoracic surgery
DiSerio 1985 Patients undergoing mastectomy and other (non-specified) types of thoracic surgery not further specified are
analysed together with those receiving thoracic lung surgery and data are not provided separately for thoracic
lung surgery
Dixon 2008 Intervention not used for primary prophylaxis of VTE
Dong 2011 Intervention not used for primary prophylaxis of VTE
Dyke 2006 Intervention not used for primary prophylaxis of VTE
Eitz 2008 Intervention not used for primary prophylaxis of VTE
Francis 2003 Intervention not used for primary prophylaxis of VTE
Gallus 1993 Both abdominal and thoracic surgery included and data not provided separately for thoracic surgery
Ghaffari 2011 Intervention not used for primary prophylaxis of VTE
Gherli 2004 Intervention not used for primary prophylaxis of VTE
Gohlke 1981 Intervention not used for primary prophylaxis of VTE
Haas 2012 Not a RCT
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(Continued)
Hartshorn 1969 Not relevant to the target population
Hassouna 2000 Intervention not used for primary prophylaxis of VTE
Hayashi 1994 Intervention not used for primary prophylaxis of VTE
Hering 2005 Intervention not used for primary prophylaxis of VTE
Iliuta 2003 Intervention not used for primary prophylaxis of VTE
Jackaman 1978 Not a RCT
Jensen 2004 Population included represented by children
Kaiser 1981 Intervention not used for primary prophylaxis of VTE
Kawazoe 1990 Not a RCT and intervention not used for primary prophylaxis of VTE
Keidan 2004 Population included represented by children
Koertke 2000 Intervention not used for primary prophylaxis of VTE
Koertke 2003 Intervention not used for primary prophylaxis of VTE
Koertke 2007 Intervention not used for primary prophylaxis of VTE
Koertke 2010 Intervention not used for primary prophylaxis of VTE
Konkle 2001 Not a RCT: randomisation regards only preoperative heparin, whereas post-surgery prophylaxis is not assigned
randomly
Kuitunen 1997 Intervention not used for primary prophylaxis of VTE
Körtke 2001 Not a RCT and intervention not used for primary prophylaxis of VTE
Laffort 2000 Intervention not used for primary prophylaxis of VTE
Liezorovicz 1991 Abdominal, gynaecological, urological, and thoracic surgery included and data not provided separately for
thoracic surgery
Ljungstrom 1985 Not a RCT and intervention not used for primary prophylaxis of VTE
Mehta 2007 Population included not undergoing surgery cardiac or thoracic surgery, and intervention not used for primary
prophylaxis of VTE
Meschengieser 1997 Intervention not used for primary prophylaxis of VTE
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(Continued)
Mirow 2001 Intervention not used for primary prophylaxis of VTE
Mok 1985 Intervention not used for primary prophylaxis of VTE
Monagle 2011 Population included represented by children
Montalescot 2000 Not a RCT and intervention not used for primary prophylaxis of VTE
Ovrum 1996 Intervention not used for primary prophylaxis of VTE
Pappalardo 2006 Intervention not used for primary prophylaxis of VTE
Pengo 1997 Intervention not used for primary prophylaxis of VTE
Pengo 2007 Intervention not used for primary prophylaxis of VTE
Pessotti 2012 Population included represented by children
Pogliani 1982 Intervention not used for primary prophylaxis of VTE
Pogliani 1993 Intervention not used for primary prophylaxis of VTE
Pruefer 2001 Intervention not used for primary prophylaxis of VTE
Rafiq 2013 Intervention not used for primary prophylaxis of VTE
Renda 2007 Intervention not used for primary prophylaxis of VTE
Samama 1988 Abdominal, gynaecological, urological, and thoracic surgery included and data not provided separately for
thoracic surgery
Saour 1990 Intervention not used for primary prophylaxis of VTE
Schlitt 2003 Intervention not used for primary prophylaxis of VTE
Segesser 1992 Intervention not used for primary prophylaxis of VTE
Starkman 1982 Intervention not used for primary prophylaxis of VTE
Swiniarska 2009 Intervention not used for primary prophylaxis of VTE
Torella 2010 Intervention not used for primary prophylaxis of VTE
Turpie 1988 Intervention not used for primary prophylaxis of VTE
Turpie 1993 Intervention not used for primary prophylaxis of VTE
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(Continued)
van der Meer 1994 Intervention not used for primary prophylaxis of VTE
Voith 1997 Intervention not used for primary prophylaxis of VTE
Walenga 2001 Intervention not used for primary prophylaxis of VTE
Warkentin 2013 Intervention not used for primary prophylaxis of VTE
Xia 2011 General surgery included and data not provided separately for thoracic surgery
RCT: randomised controlled trial
VTE: venous thromboembolism
Characteristics of studies awaiting assessment [ordered by study ID]
Avidan 2011
Methods Randomised, double-blind study
Participants Adult patients (n = 120) scheduled for elective cardiac (n = 40) or thoracic surgery (n = 80)
Interventions Intervention: desirudin (Iprivask; Canyon Pharmaceuticals, Hunt Valley, Maryland) 15 mg sc twice daily
Control: unfractionated heparin 5000 units sc thrice daily with saline placebo given once daily
Duration of thrombosis prophylaxis was determined by the treating physician
Quote: “Both treatment groups also received mechanical prophylaxis via sequential compression devices. All patients
who underwent cardiac surgery received heparin during the procedure. For these patients, enrolment into the study
occurred if thrombosis prophylaxis was required at any time from postoperative day 1 through the end of hospitaliza-
tion and if no exclusion criteria were met. Thoracic surgery patients who were assigned to the heparin treatment arm
received heparin during the procedure; those assigned to the desirudin arm received desirudin during the procedure.
For these patients, enrolment occurred when the patient received the first dose of thrombosis prophylaxis either pre-
or intra-operatively.”
Outcomes Primary outcome: incidence of new antibody formation directed against platelet factor 4 (PF4)/heparin complex
Secondary outcomes included bleeding and thrombotic complications (symptomatic and asymptomatic deep vein
thrombosis or symptomatic pulmonary embolism)
Notes This study included patients undergoing surgery types representing exclusion criteria for this review. The authors
have been contacted to try to obtain data for the patients matching the review inclusion criteria
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Ciavarella 1985
Methods Double-blind study. Other methodological aspects are unclear since the full text is not yet available
Participants Patients with prosthetic heart valves
Interventions Dipyridamole and warfarin
Outcomes Unclear, full text not retrieved
Notes -
Rajah 1983
Methods RCT
Participants Patients (n = 327) undergoing major thoracic surgery
Interventions - Heparin 5000 IU subcutaneous
- Low-dose heparin 2500 IU subcutaneous plus dihydroergotamine 0.5 mg subcutaneous
- No thromboprophylaxis
Study treatment was given tid for 10 days after surgery
Outcomes DVT. 125I fibrinogen uptake scan was used to diagnose DVT and all patients with a positive scan had a bilateral
ascending venography to confirm the diagnosis
Notes The type of thoracic surgery is not specified thus it remains unclear whether this study fulfils the inclusion criteria
of the review
Ranucci 2013
Methods Phase II, single-centre, single-blinded, RCT
Participants Patients of at least 18 years undergoing an elective heart surgery with cardiopulmonary bypass. To be eligible, patients
had to present a baseline antithrombin activity < 100% and > 60%
Interventions Intervention: antithrombin (purifiedhumanplasma derived antithrombin, Anbinex; InstitutoGrifols S.A., Barcelona,
Spain) administered immediately after anaesthesia induction as a single dose targeted to achieve a level of antithrombin
activity of 120%
Control: no antithrombin
Quote: “Unfractionated heparinwas intraoperatively administered before cardiopulmonary bypass to reach andmain-
tain a target activated clotting time of 450 seconds during CPB.” “..Further heparin doses during cardiopulmonary
bypass were administered as a bolus of 100 IU/kg if needed to maintain the desired activated clotting time value.”
Outcomes Primary: antithrombin activity levels at admission and percentage of patients with antithrombin activity < 58%
Secondary efficacy: heparin resistance, blood loss, number of plasma and packed red cells units needed during the
intensive care unit (ICU) stay, mechanical ventilation duration, ICU and hospital stay
Safety outcomes: surgical re-exploration, low cardiac output syndrome, myocardial infarction, adverse neurologic
outcome, acute kidney injury, thromboembolic events (myocardial infarction, stroke, mesenteric infarction, or pe-
ripheral or pulmonary thromboembolism), and in-hospital mortality
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Ranucci 2013 (Continued)
Notes This study reported pulmonary embolism as a secondary safety outcome in the methods section, but no information
is provided in the results section. The authors have been contacted to try to obtain this information
DVT: deep vein thrombosis
RCT: randomised clinical trial
Characteristics of ongoing studies [ordered by study ID]
Dixon 2013
Trial name or title “Use of heparin to prevent lung microvascular thrombosis in patients administered aprotinin undergoing
cardiac surgery for ischemic heart disease for ischemic heart disease”
Methods Phase II, RCT, blinded
Participants Patients 18 years or older undergoing elective cardiac surgery
Interventions Intervention: heparin intravenous infusion (18U/kg/hr) over the 3 hours prior to commencement of surgery
Control: placebo (equivalent infusion of 5% dextrose with no active drug
Outcomes Primary outcome: evidence of microvascular thrombosis on lung biopsy taken at the end of cardiac surgery
Secondary outcome: alveolar dead space
Starting date 2006
Contact information barry.dixon@svhm.org.au
Notes Trial ID: ACTRN12606000328572. The study is not yet recruiting
Meyer 2011
Trial name or title “Effect of low molecular weight heparin on survival of stage I, II or IIIA non small cell lung cancer. A
multicenter, open, randomised controlled trial”
Methods Phase III, prospective, multicentric, randomised, open trial in parallel groups with a blind adjudication of all
endpoint criteria
Participants Patientswith completely resectednon-small cell lung cancer of stage I, II, or IIIAT3N1confirmedby histology.
Patients who had preoperative chemotherapy, those who are selected for adjuvant chemotherapy and those
who are not candidates for adjuvant chemotherapy (because they have a contraindication to chemotherapy
or they have a stage I cancer) are eligible for the study
Interventions Tinzaparin sodium 100 UI/kg od for 12 weeks along with usual postoperative care including chemotherapy
Control: usual postoperative care including chemotherapy
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Meyer 2011 (Continued)
Outcomes Primary endpoint: overall 3-year mortality
Secondary outcomes: major bleeding time, symptomatic VTE, cancer-related mortality, disease-free survival
Starting date June 2007
Contact information Guy Meyer guy.meyer@egp.aphp.fr
Notes ClinicalTrials.gov Identifier: NCT00475098
NCT00789399
Trial name or title “A study of the efficacy of preventive dosing of fondaparinux sodium versus placebo for the prevention of
venous thromboembolism (VTE) inpatients undergoing coronary bypass surgery receiving routinemechanical
prophylaxis”
Methods Prospective, single-centre, phase II randomised study, single-blind (investigator)
Participants Consecutive patients aged 18 years or older undergoing isolated or redo isolated CABG
Interventions Fondaparinux (2.5 mg subcutaneous daily) starting 12 +/- 2 hours post-wound closure or the following day
in the morning (at the discretion of the cardiothoracic surgeon). The second dose would be administered 24
hours later and the dosing will then be once a day
The group randomised to placebo will receive subcutaneous equivalent volume of isotonic saline at the same
time points described above
Patients will receive fondaparinux or placebo for a total of 3 to 9 days post CABG with day 1 being the day of
surgery. The drug will be discontinued if the patient is discharged before day 9. If the patient stays for more
than 9 days inside hospital, a duplex would be obtained per protocol and further DVT prevention measures
would be instituted per the discretion of treating physician
Both groups will receive routine mechanical prophylaxis as determined by the treating physicians
Outcomes Primary outcome: rate of asymptomatic proximal DVT
Secondary outcome: asymptomatic distal DVT
Starting date October 2009
Contact information Cynthia Deitrick (cdeitrick@prairieresearch.com). Principal investigator: Raghu Kolluri
Notes ClinicalTrials.gov identifier: NCT00789399
NCT01267305
Trial name or title “The impact of different anticoagulant therapy on haemorrhage and coagulation after thoracic surgery”
Methods Randomised, open-label
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NCT01267305 (Continued)
Participants Patients with a clinical diagnosis of oesophageal carcinoma and planned for oesophagectomy or patients with
a clinical diagnosis of lung carcinoma and planned for lung resection
Interventions Nadroparin Calcium 4100 Axa IU once daily after operation
Nadroparin Calcium 4100 Axa IU twice daily after operation
Fondaparinux 2.5 mg IH once daily after operation
Outcomes Primary outcome: thromboelastography values
Secondary outcomes: bleeding quantity of chest drainage, incidence rate of DVT, in-hospital mortality
Starting date January 2011
Contact information Principal investigator: Lizhen Xuan, Shanghai Zhongshan Hospital
Notes ClinicalTrials.gov Identifier: NCT01267305
CABG: coronary artery bypass surgery
DVT: deep vein thrombosis
HIT: heparin-induced thrombocytopaenia
OD: once daily
VTE: venous thromboembolism
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D A T A A N D A N A L Y S E S
Comparison 1. Cardiac surgery: symptomatic VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 Intermittent pneumatic
compression plus graded elastic
compression stockings versus
graded elastic compression
stockings
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
3 UFH plus IPC versus UFH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
4 UFH plus aspirin versus UFH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 2. Thoracic surgery: symptomatic VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Heparin versus inactive control 3 2458 Risk Ratio (IV, Random, 95% CI) 6.71 [0.40, 112.65]
1.1 UFH versus placebo 1 29 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 UFH versus no UFH 2 2429 Risk Ratio (IV, Random, 95% CI) 6.71 [0.40, 112.65]
2 UFH versus defibrotide 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
3 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
4 Fixed-dose LMWH versus
weight-adjusted dose LMWH
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 3. Cardiac surgery: major bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 VKAs versus platelet inhibitor 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 3-month VKAs versus 3-month
platelet inhibitor
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 4. Thoracic surgery: major bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 Fixed-dose LMWH versus
weight-adjusted dose LMWH
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 5. Cardiac surgery: overall VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 Intermittent pneumatic
compression plus graded elastic
compression stockings versus
graded elastic compression
stockings
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
3 VKAs versus platelet inhibitor 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
4 3-month VKAs versus 3-month
platelet inhibitor
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
5 UFH plus aspirin versus UFH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 6. Thoracic surgery: overall VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UFH versus inactive control 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
3 Fixed-dose LMWH versus
weight-adjusted dose LMWH
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
4 UFH versus VKAs 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 7. Cardiac surgery: overall mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 VKAs versus platelet inhibitor 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 3-month VKAs versus 3-month
platelet inhibitor
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 8. Cardiac surgery: minor bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 VKAs versus platelet inhibitor 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
3 3-month VKAs versus 3-month
platelet inhibitor
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
4 UFH plus aspirin versus UFH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 9. Thoracic surgery: minor bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UFH versus LMWH 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 Fixed-dose LMWH versus
weight-adjusted dose LMWH
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 10. Thoracic surgery: serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fixed-dose LMWH versus
weight-adjusted dose LMWH
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
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Comparison 11. Cardiac surgery: adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 VKAs versus platelet inhibitor 1 Risk Ratio (IV, Random, 95% CI) Totals not selected
2 3-month VKAs versus 3-month
platelet inhibitor
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Comparison 12. Thoracic surgery: adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fixed-dose LMWH versus
weight-adjusted LMWH
1 Risk Ratio (IV, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Cardiac surgery: symptomatic VTE, Outcome 1 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 1 Cardiac surgery: symptomatic VTE
Outcome: 1 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Beghi 1993 0/19 0/20 Not estimable
0.02 0.1 1 10 50
Favours UFH Favours LMWH
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Analysis 1.2. Comparison 1 Cardiac surgery: symptomatic VTE, Outcome 2 Intermittent pneumatic
compression plus graded elastic compression stockings versus graded elastic compression stockings.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 1 Cardiac surgery: symptomatic VTE
Outcome: 2 Intermittent pneumatic compression plus graded elastic compression stockings versus graded elastic compression stockings
Study or subgroup
Favours
IPC plus
GCS GCS Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Goldhaber 1995 1/164 1/166 1.01 [ 0.06, 16.05 ]
0.002 0.1 1 10 500
Favours IPC plus GCS Favours GCS
Analysis 1.3. Comparison 1 Cardiac surgery: symptomatic VTE, Outcome 3 UFH plus IPC versus UFH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 1 Cardiac surgery: symptomatic VTE
Outcome: 3 UFH plus IPC versus UFH
Study or subgroup UFH plus PCS UFH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ramos 1996 21/1355 48/1196 0.39 [ 0.23, 0.64 ]
0.02 0.1 1 10 50
Favours UFH plus PCS Favours UFH
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Analysis 1.4. Comparison 1 Cardiac surgery: symptomatic VTE, Outcome 4 UFH plus aspirin versus UFH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 1 Cardiac surgery: symptomatic VTE
Outcome: 4 UFH plus aspirin versus UFH
Study or subgroup UFH plus aspirin UFH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Mirhosseini 2013 0/60 0/60 Not estimable
0.01 0.1 1 10 100
Favours UFH plus aspirin Favours UFH
Analysis 2.1. Comparison 2 Thoracic surgery: symptomatic VTE, Outcome 1 Heparin versus inactive
control.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 2 Thoracic surgery: symptomatic VTE
Outcome: 1 Heparin versus inactive control
Study or subgroup Heparin Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 UFH versus placebo
Marchetti 1983 0/16 0/13 Not estimable
Subtotal (95% CI) 16 13 Not estimable
Total events: 0 (Heparin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 UFH versus no UFH
Gallus 1973 0/4 0/5 Not estimable
Le Brigand 1981 13/1939 0/481 100.0 % 6.71 [ 0.40, 112.65 ]
Subtotal (95% CI) 1943 486 100.0 % 6.71 [ 0.40, 112.65 ]
Total events: 13 (Heparin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
0.005 0.1 1 10 200
Favours heparin Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Heparin Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 1959 499 100.0 % 6.71 [ 0.40, 112.65 ]
Total events: 13 (Heparin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours heparin Favours control
Analysis 2.2. Comparison 2 Thoracic surgery: symptomatic VTE, Outcome 2 UFH versus defibrotide.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 2 Thoracic surgery: symptomatic VTE
Outcome: 2 UFH versus defibrotide
Study or subgroup UFH Defibrotide Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Rizzi 1987 2/90 0/94 5.22 [ 0.25, 107.25 ]
0.002 0.1 1 10 500
Favours UFH Favours defibrotide
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Analysis 2.3. Comparison 2 Thoracic surgery: symptomatic VTE, Outcome 3 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 2 Thoracic surgery: symptomatic VTE
Outcome: 3 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Dahan 1990 0/50 0/50 Not estimable
0.5 0.7 1 1.5 2
Favours UFH Favours LMWH
Analysis 2.4. Comparison 2 Thoracic surgery: symptomatic VTE, Outcome 4 Fixed-dose LMWH versus
weight-adjusted dose LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 2 Thoracic surgery: symptomatic VTE
Outcome: 4 Fixed-dose LMWH versus weight-adjusted dose LMWH
Study or subgroup Fixed dose Adjusted dose Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Azorin 1997 0/74 0/74 Not estimable
0.5 0.7 1 1.5 2
Favours fixed dose Favours adjusted dose
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Analysis 3.1. Comparison 3 Cardiac surgery: major bleeding, Outcome 1 VKAs versus platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 3 Cardiac surgery: major bleeding
Outcome: 1 VKAs versus platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 14/124 2/125 7.06 [ 1.64, 30.40 ]
0.001 0.01 0.1 1 10 100 1000
Favours VKAs Favours platelet inhibitor
Analysis 3.2. Comparison 3 Cardiac surgery: major bleeding, Outcome 2 3-month VKAs versus 3-month
platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 3 Cardiac surgery: major bleeding
Outcome: 2 3-month VKAs versus 3-month platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 5/65 2/63 2.42 [ 0.49, 12.04 ]
0.01 0.1 1 10 100
Favours VKAs Favours platelet inhibitor
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Analysis 4.1. Comparison 4 Thoracic surgery: major bleeding, Outcome 1 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 4 Thoracic surgery: major bleeding
Outcome: 1 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Dahan 1990 3/50 2/50 1.50 [ 0.26, 8.60 ]
0.01 0.1 1 10 100
Favours UFH Favours LMWH
Analysis 4.2. Comparison 4 Thoracic surgery: major bleeding, Outcome 2 Fixed-dose LMWH versus
weight-adjusted dose LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 4 Thoracic surgery: major bleeding
Outcome: 2 Fixed-dose LMWH versus weight-adjusted dose LMWH
Study or subgroup Fixed dose Adjusted dose Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Azorin 1997 2/74 6/74 0.33 [ 0.07, 1.60 ]
0.005 0.1 1 10 200
Favours fixed dose Favours adjusted dose
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Analysis 5.1. Comparison 5 Cardiac surgery: overall VTE, Outcome 1 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 5 Cardiac surgery: overall VTE
Outcome: 1 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Beghi 1993 0/19 0/20 Not estimable
0.5 0.7 1 1.5 2
Favours UFH Favours LMWH
Analysis 5.2. Comparison 5 Cardiac surgery: overall VTE, Outcome 2 Intermittent pneumatic compression
plus graded elastic compression stockings versus graded elastic compression stockings.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 5 Cardiac surgery: overall VTE
Outcome: 2 Intermittent pneumatic compression plus graded elastic compression stockings versus graded elastic compression stockings
Study or subgroup IPC plus GCS GCS Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Goldhaber 1995 31/164 36/166 0.87 [ 0.57, 1.34 ]
0.1 0.2 0.5 1 2 5 10
Favours IPC plus GCS Favours GCS
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Analysis 5.3. Comparison 5 Cardiac surgery: overall VTE, Outcome 3 VKAs versus platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 5 Cardiac surgery: overall VTE
Outcome: 3 VKAs versus platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 0/124 4/125 0.11 [ 0.01, 2.06 ]
0.002 0.1 1 10 500
Favours VKAs Favours platelet inhibitor
Analysis 5.4. Comparison 5 Cardiac surgery: overall VTE, Outcome 4 3-month VKAs versus 3-month
platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 5 Cardiac surgery: overall VTE
Outcome: 4 3-month VKAs versus 3-month platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 0/65 3/63 0.14 [ 0.01, 2.63 ]
0.001 0.01 0.1 1 10 100 1000
Favours VKAs Favours platelet inhibit
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Analysis 5.5. Comparison 5 Cardiac surgery: overall VTE, Outcome 5 UFH plus aspirin versus UFH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 5 Cardiac surgery: overall VTE
Outcome: 5 UFH plus aspirin versus UFH
Study or subgroup UFH plus aspirin UFH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Mirhosseini 2013 2/60 10/60 0.20 [ 0.05, 0.87 ]
0.01 0.1 1 10 100
Favours UFH plus aspirin Favours UFH
Analysis 6.1. Comparison 6 Thoracic surgery: overall VTE, Outcome 1 UFH versus inactive control.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 6 Thoracic surgery: overall VTE
Outcome: 1 UFH versus inactive control
Study or subgroup UFH Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Gallus 1973 0/4 0/5 Not estimable
0.5 0.7 1 1.5 2
Favours UFH Favours control
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Analysis 6.2. Comparison 6 Thoracic surgery: overall VTE, Outcome 2 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 6 Thoracic surgery: overall VTE
Outcome: 2 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Dahan 1990 0/50 0/50 Not estimable
0.5 0.7 1 1.5 2
Favours UFH Favours LMWH
Analysis 6.3. Comparison 6 Thoracic surgery: overall VTE, Outcome 3 Fixed-dose LMWH versus weight-
adjusted dose LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 6 Thoracic surgery: overall VTE
Outcome: 3 Fixed-dose LMWH versus weight-adjusted dose LMWH
Study or subgroup Fixed dose Adjusted dose Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Azorin 1997 1/74 0/74 3.00 [ 0.12, 72.47 ]
0.002 0.1 1 10 500
Favours fixed dose Favours adjusted dose
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Analysis 6.4. Comparison 6 Thoracic surgery: overall VTE, Outcome 4 UFH versus VKAs.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 6 Thoracic surgery: overall VTE
Outcome: 4 UFH versus VKAs
Study or subgroup UFH VKAs Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
van Geloven 1977 3/19 5/22 0.69 [ 0.19, 2.53 ]
0.01 0.1 1 10 100
Favours UFH Favours VKAs
Analysis 7.1. Comparison 7 Cardiac surgery: overall mortality, Outcome 1 VKAs versus platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 7 Cardiac surgery: overall mortality
Outcome: 1 VKAs versus platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 8/124 2/125 4.03 [ 0.87, 18.61 ]
0.01 0.1 1 10 100
Favours VKAs Favours platelet inhibitor
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Analysis 7.2. Comparison 7 Cardiac surgery: overall mortality, Outcome 2 3-month VKAs versus 3-month
platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 7 Cardiac surgery: overall mortality
Outcome: 2 3-month VKAs versus 3-month platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 4/65 1/63 3.88 [ 0.45, 33.74 ]
0.005 0.1 1 10 200
Favours VKAs Favours platelet inhibitor
Analysis 8.1. Comparison 8 Cardiac surgery: minor bleeding, Outcome 1 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 8 Cardiac surgery: minor bleeding
Outcome: 1 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Beghi 1993 4/19 0/20 9.45 [ 0.54, 164.49 ]
0.001 0.01 0.1 1 10 100 1000
Favours UFH Favours LMWH
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Analysis 8.2. Comparison 8 Cardiac surgery: minor bleeding, Outcome 2 VKAs versus platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 8 Cardiac surgery: minor bleeding
Outcome: 2 VKAs versus platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 6/124 3/125 2.02 [ 0.52, 7.88 ]
0.005 0.1 1 10 200
Favours VKAs Favours platelet inhibitor
Analysis 8.3. Comparison 8 Cardiac surgery: minor bleeding, Outcome 3 3-month VKAs versus 3-month
platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 8 Cardiac surgery: minor bleeding
Outcome: 3 3-month VKAs versus 3-month platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 1/65 1/63 0.97 [ 0.06, 15.16 ]
0.001 0.01 0.1 1 10 100 1000
Favours VKAs Favours platelet inhibitor
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Analysis 8.4. Comparison 8 Cardiac surgery: minor bleeding, Outcome 4 UFH plus aspirin versus UFH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 8 Cardiac surgery: minor bleeding
Outcome: 4 UFH plus aspirin versus UFH
Study or subgroup UFH plus aspirin UFH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Mirhosseini 2013 4/60 1/60 4.00 [ 0.46, 34.75 ]
0.01 0.1 1 10 100
Favours UFH plus aspirin Favours UFH
Analysis 9.1. Comparison 9 Thoracic surgery: minor bleeding, Outcome 1 UFH versus LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 9 Thoracic surgery: minor bleeding
Outcome: 1 UFH versus LMWH
Study or subgroup UFH LMWH Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Dahan 1990 8/50 2/50 4.00 [ 0.89, 17.91 ]
0.005 0.1 1 10 200
Favours UFH Favours LMWH
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Analysis 9.2. Comparison 9 Thoracic surgery: minor bleeding, Outcome 2 Fixed-dose LMWH versus
weight-adjusted dose LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 9 Thoracic surgery: minor bleeding
Outcome: 2 Fixed-dose LMWH versus weight-adjusted dose LMWH
Study or subgroup Fixed dose Adjusted dose Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Azorin 1997 1/74 2/74 0.50 [ 0.05, 5.40 ]
0.002 0.1 1 10 500
Favours fixed dose Favours adjusted dose
Analysis 10.1. Comparison 10 Thoracic surgery: serious adverse events, Outcome 1 Fixed-dose LMWH
versus weight-adjusted dose LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 10 Thoracic surgery: serious adverse events
Outcome: 1 Fixed-dose LMWH versus weight-adjusted dose LMWH
Study or subgroup Fixed dose Adjusted dose Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Azorin 1997 2/74 3/74 0.67 [ 0.11, 3.87 ]
0.01 0.1 1 10 100
Favours fixed dose Favours adjusted dose
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Analysis 11.1. Comparison 11 Cardiac surgery: adverse events, Outcome 1 VKAs versus platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 11 Cardiac surgery: adverse events
Outcome: 1 VKAs versus platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 6/124 20/125 0.30 [ 0.13, 0.73 ]
0.001 0.01 0.1 1 10 100 1000
Favours VKAs Favours platelet inhibitor
Analysis 11.2. Comparison 11 Cardiac surgery: adverse events, Outcome 2 3-month VKAs versus 3-month
platelet inhibitor.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 11 Cardiac surgery: adverse events
Outcome: 2 3-month VKAs versus 3-month platelet inhibitor
Study or subgroup VKAs Platelet inhibitor Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Pfisterer 1989 2/65 12/63 0.16 [ 0.04, 0.69 ]
0.002 0.1 1 10 500
Favours VKAs Favours platelet inhibitor
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Analysis 12.1. Comparison 12 Thoracic surgery: adverse events, Outcome 1 Fixed-dose LMWH versus
weight-adjusted LMWH.
Review: Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
Comparison: 12 Thoracic surgery: adverse events
Outcome: 1 Fixed-dose LMWH versus weight-adjusted LMWH
Study or subgroup Fixed dose Adjusted dose Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Azorin 1997 3/74 3/74 1.00 [ 0.21, 4.79 ]
0.005 0.1 1 10 200
Favours fixed dose Favours adjusted dose
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1126
#2 MESH DESCRIPTOR Thromboembolism 838
#3 MESH DESCRIPTOR Venous Thromboembolism 155
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
1853
#5 (thromboprophyla* or thrombus* or thrombotic* or throm-
bolic* or thromboemboli* or thrombos* or embol*):TI,AB,
KY
12097
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
674
#7 (PE or DVT or VTE):TI,AB,KY 2635
#8 (((vein* or ven*) near thromb*)):TI,AB,KY 4579
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 14035
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(Continued)
#10 MESH DESCRIPTOR Cardiac Surgical Procedures EX-
PLODE ALL TREES
10324
#11 MESH DESCRIPTOR Thoracic Surgery 139
#12 Sternotomy:TI,AB,KY 415
#13 (thoracoplasty or thoracostomy):TI,AB,KY 101
#14 Thoracoscopy:TI,AB,KY 163
#15 (pneumonectomy or pneumectomy):TI,AB,KY 433
#16 Thoracotomy:TI,AB,KY 947
#17 Thymectomy:TI,AB,KY 48
#18 Tracheostomy:TI,AB,KY 268
#19 Tracheotomy:TI,AB,KY 111
#20 (cardiac near5 surg*):TI,AB,KY 4210
#21 ((cardio* or coronary or heart) near5 (surg* or bypass or stent*
or valve*)):TI,AB,KY
13053
#22 ((thora* or lung or trachea*) near5 surgery):TI,AB,KY 2127
#23 ((heart or lung) near5 transplant*):TI,AB,KY 1111
#24 (myocardial near5 surg*):TI,AB,KY 906
#25 (pericardi* near5 surg*):TI,AB,KY 56
#26 MESH DESCRIPTOR Endocardium WITH QUALIFIERS
SU
2
#27 MESH DESCRIPTOR Fetal Heart EXPLODE ALL TREES
WITH QUALIFIERS SU
1
#28 MESHDESCRIPTOR Heart Atria EXPLODE ALL TREES
WITH QUALIFIERS SU
84
#29 MESH DESCRIPTOR Heart Conduction System EX-
PLODE ALL TREES WITH QUALIFIERS SU
120
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(Continued)
#30 MESH DESCRIPTOR Heart Septum EXPLODE ALL
TREES WITH QUALIFIERS SU
24
#31 MESHDESCRIPTORHeartValves EXPLODEALLTREES
WITH QUALIFIERS SU
445
#32 MESH DESCRIPTOR Heart Ventricles EXPLODE ALL
TREES WITH QUALIFIERS SU
71
#33 MESH DESCRIPTOR Papillary Muscles EXPLODE ALL
TREES WITH QUALIFIERS SU
6
#34 MESHDESCRIPTORPericardiumEXPLODEALLTREES
WITH QUALIFIERS SU
19
#35 MESH DESCRIPTOR Lung EXPLODE ALL TREES
WITH QUALIFIERS SU
110
#36 MESH DESCRIPTOR Trachea EXPLODE ALL TREES
WITH QUALIFIERS SU
18
#37 MESH DESCRIPTOR Esophagus EXPLODE ALL TREES
WITH QUALIFIERS SU
154
#38 MESHDESCRIPTORDiaphragm EXPLODE ALL TREES
WITH QUALIFIERS SU
0
#39 MESH DESCRIPTOR Thoracic Cavity EXPLODE ALL
TREES WITH QUALIFIERS SU
13
#40 MESHDESCRIPTOR Thoracic Wall WITHQUALIFIERS
SU
2
#41 MESHDESCRIPTORRibs EXPLODEALLTREESWITH
QUALIFIERS SU
9
#42 MESH DESCRIPTOR Sternum EXPLODE ALL TREES
WITH QUALIFIERS SU
135
#43 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR
#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR
#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR
#38 OR #39 OR #40 OR #41 OR #42
20952
#44 #9 AND #43 1739
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we planned to estimate the between-trial heterogeneity of the results with the I2 statistic (Higgins 2003; Rücker 2008).
However, the paucity of data precluded the evaluation of heterogeneity either with the I2 statistic, or with the Tau2, as currently
advised by theCochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Similarly, the low number of studies identified
precluded any exploration of the effects of trial characteristics such as the type of lesion operated (malignant versus benign in non-
cardiac thoracic surgery trials), type of cardiac surgery (coronary artery bypass grafting versus valve surgery), urgent versus elective
procedure, and quality items on symptomatic VTE or major bleeding. Similarly, the effect of sub-optimal design choices and biases
related to small study size could not be evaluated. We aimed to use GRADE to describe the quality of the overall body of evidence
(Guyatt 2008; Higgins 2011). As we could not statistically pool any outcome data across trials, we omitted the ’Summary of findings’
table with GRADE assessment. The exclusion criterion “video assisted thoracic surgery”, which was specified in the protocol, was
subsequently removed at the review stage since it was in conflict with the inclusion criterion “thoracoscopic lung surgery”. Although
the search did not exclude studies on video assisted thoracic surgery nor thoracoscopic lung surgery, we retrieved no such studies.
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